

CTAD Alzheimer 2022

Clinical Trials on Alzheimer's Disease

Preliminary program



ONSITE



ONLINE

November 29 - December 2, 2022
San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

www.ctad-alzheimer.com

Email: ctad@ant-congres.com





SUMMARY

Editorial	3
Organizing & Scientific Committees	4
Lifetime Achievement Award	5
Keynotes	6
Program at a glance	9
Onsite Program	
Tuesday, November 29	10
Wednesday, November 30	11
Thursday, December 1	14
Friday, December 2	16
Poster presentations	20

Editorial

Dear colleagues,

The field of Alzheimer's disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held this **November 29-December 2, 2022**, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer's disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer's disease have shown great promise for screening, and even for diagnosis.

But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco this Fall. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the worlds' largest biotech hub just south of the city, and Silicon Valley further south. Don't forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I'm looking forward to seeing old friends, and making new ones at the CTAD meeting this Fall in beautiful San Francisco.

Dr. Mike Weiner
President of the CTAD22 Scientific Committee





President of the CTAD22 Scientific Committee

Michael W. WEINER, MD
University of California at San Francisco (UCSF)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachele DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

* Organizing Committee Member

CTAD 2022 Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Reisa Sperling MD, Ph.D. and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.



Reisa SPERLING MD, PhD

Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the pre-symptomatic or "preclinical" stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer's Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.



Keith JOHNSON MD

Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women's Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies.

Keynotes



“The Current and Future State of AD plasma biomarkers”

Kaj Blennow, MD, PhD

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110.000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF and blood biomarkers.



“Targeting Immuno-Metabolic Pathways in Alzheimer’s Disease: Novel Mechanisms and Therapeutic Opportunities”

Suzanne Craft, PhD

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium. Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO’s Emmy-award winning series “The Alzheimer’s Project: Momentum in Science”, in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.

Keynotes



“Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions”

Miia Kivipelto, MD, PhD

Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Miia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-



“Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease”

Roger Nitsch, MD

CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.

A large audience is seated in a conference hall, facing a stage. Two large presentation screens are visible on the stage, displaying a slide titled "High dose regimen: Individual-level dosing". The audience is diverse in age and appearance, and many are looking towards the stage. The room has a high ceiling with exposed lighting rigs and speakers. The overall atmosphere is professional and focused.

**ONSITE
PROGRAM**
in San Francisco
Available via livestream
on the CTAD22
digital platform

Program at a glance

● Tuesday, NOVEMBER 29

- 4.00 p.m. Opening Ceremony and CTAD Lifetime Achievement Award
- 4.30 p.m. **KEYNOTE 1:** Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
- 4.50 p.m. **Lecanemab Phase 3 Topline Results**
- 6.30 p.m. CTAD Welcome Reception

● Wednesday, NOVEMBER 30

- 9.00 a.m. **KEYNOTE 2:** Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
- 9.20 a.m. **SYMPOSIUM 1:** CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
- 10.00 a.m. Coffee break and poster session
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 12.15 p.m. Lunch and poster sessions
- 1.20 p.m. **SYMPOSIUM 2:** Decentralization Approaches for Clinical Trials on Alzheimer's Disease
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** New Insights for Amyloid and Tau PET Imaging
- 3.00 p.m. **LATE BREAKING COMMUNICATIONS**
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. **Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab**

● Thursday, DECEMBER 1

- 9.00 a.m. **KEYNOTE 3:** The Current and Future State of AD plasma biomarkers
- 9.20 a.m. **Anti Amyloid Phase 3 results: A CTAD open discussion**
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Beyond Amyloid and Tau: Emerging solutions
- 10.50 a.m. Coffee break and poster session
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
- 12.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 12.20 p.m. Lunch and poster sessions
- 1.30 p.m. **ORAL COMMUNICATIONS**
- 2.30 p.m. **ROUNDTABLE 1:** Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments
- 3.00 p.m. **ORAL COMMUNICATIONS**
- 3.50 p.m. Coffee break and poster session
- 4.15 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

● Friday, DECEMBER 2

- 9.00 a.m. **KEYNOTE 4:** Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 10.20 a.m. Coffee break and poster session
- 10.45 a.m. **ROUNDTABLE 2:** The Alzheimer's disease Patient Pathway from a sex and gender lens
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Interim or preliminary data and study design
- 11.55 a.m. **ORAL COMMUNICATIONS**
- 12.40 p.m. Lunch and poster sessions
- 1.30 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Clinical Trials Phase 1 Results
- 2.00 p.m. **ORAL COMMUNICATIONS**

● Tuesday, NOVEMBER 29

- 4.00 p.m **Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research**
Presented to Reisa Sperling MD, PhD and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research
Introduction by Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA)*, Jacques Touchon, *Montpellier University, Montpellier (France)*, Bruno Vellas, *Gerontopole, Toulouse University, Toulouse (France)*, Mike Weiner, *UCSF, San Francisco, CA (USA)*
- 4.30 p.m **KEYNOTE 1**
Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
Suzanne Craft, *Wake Forest University School of Medicine, Winston-Salem, NC (USA)*
- 4.50 p.m **Lecanemab Phase 3 Topline Results**
- 6.30 p.m **CTAD Welcome Reception**
- 7.30 p.m **End of the Conference Day**



● Wednesday, NOVEMBER 30



- 9.00 a.m. **KEYNOTE 2**
Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
Miia Kivipelto, Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)
- 9.20 a.m. **SYMPOSIUM 1**
CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
Chair: Kaj Blennow, University of Gothenburg, Gothenburg (Sweden)
- Presentation 1: Relationship between blood plasma and CSF measures of A β 42/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer's disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)
- Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening
Michelle M. Mielke, Wake Forest University School of Medicine, Winston-Salem, NC (USA)
- Presentation 3: Implementation of plasma biomarkers into clinical practice and trials
Oskar Hansson, Lund University, Lund (Sweden)
- 10.00 a.m. Coffee break and poster session 
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 11.00 a.m. **OC1 - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity**
Johannes Streffer^{1,2}, Julien Mermoud¹, Olivier Sol¹, Marija Vukicevic¹, Emma Fiorini¹, Eva Gollwitzer¹, Valérie Hliva¹, David Hickman¹, Julian Gray¹, Piergiorgio Donati¹, Maria Pilar Lopez Deber¹, Julien Rongère¹, Andrea Pfeifer¹, Marie Kosco-Vilbois¹, Philip Scheltens³
¹AC Immune SA - Lausanne (Switzerland), ²University of Antwerp - Antwerp (Belgium), ³VUMC - Amsterdam (The Netherlands)
- 11.15 a.m. **OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy Bodies**
Michael Irizarry¹, Robert Lai², Steven Hersch¹, Kate Pinner², Shobha Dhadda¹, Lynn Kramer¹
¹Eisai Inc. - Nutley (United States), ²Eisai Ltd. - Hattfield (United Kingdom)
- 11.30 a.m. **OC3 - An Update on Interim Data for the First Tau Aggregation Inhibitor – Hydromethylthionine mesylate (HMTM)**
Bjoern Schelter^{1,2}
¹TauRx Therapeutics Ltd - Aberdeen (United Kingdom), ²University of Aberdeen - Aberdeen (United Kingdom)
- 11.45 a.m. **OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer's Disease**
Gallen Triana-Baltzer¹, Ziad Saad¹, Setareh Moughadam¹, Randy Slemmon¹, Mary Quiceno¹, David Henley¹, Hartmuth Kolb¹
¹Janssen Research & Development - San Diego (United States)
- 12.00 p.m. **OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT**
Sube Banerjee On Behalf Of The Symbad Group¹
¹University Of Plymouth - Plymouth (United Kingdom)
- 12.15 p.m. Lunch break and poster session

● Wednesday, NOVEMBER 30

1.20 p.m

SYMPOSIUM 2

Decentralization Approaches for Clinical Trials on Alzheimer's Disease

Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)

Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ

Jessica Langbaum, Banner Alzheimer's Institute - Phoenix, AZ (United States)

Presentation 2: Effects of supervision on cognitive and functional assessment outcomes

Paul Maruff, CogState - Melbourne (Australia)

Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3

Roy Yaari, Eli Lilly and Company – Indianapolis, IN (United States)

Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer's Disease

Elly Lee, Irvine Clinical Research – Irvine, CA (United States)

2.00 p.m

ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging

2.00 p.m

OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses

Xavier Higgins¹, Amanda Morris¹, John Sims¹, Mark Mintun¹, Sergey Shcherbinin¹

¹Eli Lilly and Company - Indianapolis (United States)

2.10 p.m

OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation

Ziad S. Saad¹, Ritobrato Datta¹, Christopher Rowe², Hartmuth C. Kolb¹

¹Janssen R&D, Johnson & Johnson - San Diego (United States), ²Austin Health and University of Melbourne - Melbourne (Australia)

2.20 p.m

OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer's disease

Antoine Leuzy¹, Alexa Pichet-Binette¹, Jacob W. Vogel², Gregory Klein³, Edilio Borroni³, Matteo Tonietto³, Olof Strandberg¹, Niklas Mattsson-Carlgrén¹, Sebastian Palmqvist¹, Erik Stomrud¹, Rik Ossenkoppele¹, Ruben Smith¹, Oskar Hansson¹

¹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), ²Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), ³F. Hoffmann-La Roche Ltd, Basel (Switzerland)

2.30 p.m

OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum

Alexis Moscoso¹, Fiona Heeman¹, Valle Camacho², Martijn Van Essen³, Michel J Grothe⁴, Li Lin⁵, Ismini Mainta⁶, Federica Ribaldi⁷, Michael D Devous⁸, Michael J Pontecorvo⁸, Giovanni B Frisoni⁷, Valentina Garibotto⁷, Michael Schöll¹

¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), ²Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), ³Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), ⁴Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, Spain. - Sevilla (Spain), ⁵Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), ⁶Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland. - Genève (Switzerland), ⁷Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), ⁸Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)

2.40 p.m

OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARLOTTE-PRO Substudy

Gerald Novak¹, Ziad Saad², David Scott³, Chi Udeh-Momoh⁴, Luc Bracoud⁵, Craig Ritchie⁶, Lefkos Middleton⁷

¹Janssen R&D - Titusville, NJ (United States), ²Janssen R&D - La Jolla, Ca (United States), ³Clario (formerly Bioclinica) - San Mateo, Ca (United States), ⁴Imperial College - London (United Kingdom), ⁵Clario (formerly Bioclinica) - Lyon (France), ⁶University of Edinburgh - Edinburgh (United Kingdom), ⁷Imperial College - Edinburgh (United Kingdom)

● Wednesday,
NOVEMBER 30



2.50 p.m **OC11 - AmyloidIQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers**
Alex Whittington¹, Santiago Bullich², Lily Porat¹, Roger Gunn¹
¹Invicro - London (United Kingdom), ²Life Molecular Imaging - Berlin (Germany)

3.00 p.m **LATE BREAKING ORAL COMMUNICATIONS**

3.45 p.m Coffee break and poster session 

4.15 p.m **Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab**

5.15 p.m **End of the Conference Day**

Thursday, DECEMBER 1

- 9.00 a.m** **KEYNOTE 3**
The Current and Future State of AD plasma biomarkers
Kaj Blennow, *University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)*
- 9.20 a.m** **Anti Amyloid Phase 3 results: A CTAD open discussion**
Maria Carrillo¹, David Knopman², Lefkos Middleton³, Ron Petersen²
¹ *Alzheimer's Association - Chicago, IL (United States)*, ² *Mayo Clinic - Rochester, MN (United States)*, ³ *Imperial College - London (United Kingdom)*
- 9.50 a.m** **ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**
Chair: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York, NY (USA)*
- 9.50 a.m** **OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**
Carl Cotman¹, Howard Feldman², Andrea Lacroix², Aladdin Shadyab², Diane Jacobs², David Salmon², Ron Thomas², Shelia Jin², Judy Pa², Jeffrey Katula³, Robert Rissman⁴, James Brewer², Youngkyoo Jung⁵, Jing Zhang², Laura Baker⁶
¹ *UCI (United States)*, ² *UCSD (United States)*, ³ *Wake Forest University (United States)*, ⁴ *USC (United States)*, ⁵ *UC Davis (United States)*, ⁶ *Wake Forest University School of Medicine (United States)*
- 10.05 a.m** **OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) – Pilot Study Results on Central Nervous System Penetration and Alzheimer's Disease Biomarkers**
Mitzi Gonzales¹, Valentina Garbarino¹, Tiffany Kautz¹, Ronald Petersen², Tamara Tchkonja², James Kirkland², Suzanne Craft³, Sudha Seshadri¹, Nicolas Musi¹, Miranda Orr³
¹ *UT Health San Antonio - San Antonio (United States)*, ² *Mayo Clinic - Rochester (United States)*, ³ *Wake Forest School Of Medicine - Winston-Salem (United States)*
- 10.20 a.m** **OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of T2001 in Alzheimer Patients**
Ronald Van Der Geest¹, Anastasia Lili¹, Sietske Sikkes², Jort Vijverberg², Philip Scheltens²
¹ *Treeway B.V. - Tilburg (Netherlands)*, ² *Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)*
- 10.35 a.m** **OC15 - Late breaking oral communication**
- 10.50 a.m** Coffee break and poster session 
- 11.20 a.m** **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
- 12.00 p.m** **LATE BREAKING ORAL COMMUNICATIONS**
- 12.20 p.m** Lunch break and poster session
- 1.30 p.m** **ORAL COMMUNICATIONS**
- 1.30 p.m** **OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials**
Dave Miller¹
¹ *Unlearn.AI - Berkeley (United States)*
- 1.45 p.m** **OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?**
Rik Ossenkoppele¹, Alexa Pichet Binette¹, Colin Groot¹, Reisa Sperling², Colin Masters³, Wiesje Van Der Flier⁴, William Jagust⁵, Petersen Ronald⁶, Clifford Jack⁶, Oskar Hansson¹
¹ *Lund University - Lund (Sweden)*, ² *MGH - Boston (United States)*, ³ *The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia)*, ⁴ *Amsterdam University Medical Center - Amsterdam (Netherlands)*, ⁵ *UC Berkeley - Berkeley (United States)*, ⁶ *Mayo Clinic - Rochester (United States)*
- 2.00 p.m** **OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts**
Andrew M. Stern¹, Kathryn L. Van Pelt², Lei Liu¹, Amirah K. Anderson¹, Beth Ostaszewski¹, Dennis J. Selkoe¹, Frederick Schmitt², Elizabeth Head³
¹ *Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States)*, ² *Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States)*, ³ *Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)*

● Thursday, DECEMBER 1



2.15 p.m **OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden**
Gemma Salvadó¹, Rik Ossenkoppele^{1,2}, Nicholas J Ashton^{3,4,5}, Thomas G Beach⁶, Geidy E Serrano⁶, Gwendlyn Kollmorgen⁷, Henrik Zetterberg^{3,8,9,10}, Shorena Janelidze¹, Kaj Blennow³, Oskar Hansson^{1,11}
¹Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), ²Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), ³Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁴Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London - London (United Kingdom), ⁵NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), ⁶Banner Sun Health Research Institute - Sun City (United States), ⁷Roche Diagnostics GmbH - Penzberg (Germany), ⁸Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁹Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), ¹⁰UK Dementia Research Institute at UCL - London (United Kingdom), ¹¹Memory Clinic, Skåne University Hospital - Malmö (Sweden)

2.30 p.m **ROUNDTABLE 1**
Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments
Chair: Niranjan Bose, Gates Ventures, Seattle, WA (United States)
Discussants: Howard Fillit, Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States); Laurence Barker, Partner in the Dementia Discovery Fund (DDF), London (United Kingdom); Philip Scheltens, LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands))

3.00 p.m ORAL COMMUNICATIONS

3.00 p.m **OC20 - Systemic inflammation and reduced cerebral A β clearance triggered by pancreatic amylin**
Florin Despa¹, Nirmal Verma¹, Edric Winford¹, Peter Nelson¹, Gregory Jicha¹, Larry Goldstein¹, Claire Troakes², Henrik Zetterberg³, John Hardy³, Tammaryn Lashley³
¹University Of Kentucky - Lexington (United States), ²King's College London - London (United Kingdom), ³Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m **OC21 - Prazosin for Agitation in Alzheimer's Disease: PEACE-AD**
Elaine Peskind¹, Murray Raskind², Ronald Thomas³, Gregory Jicha⁴, Neela Patel⁵, Amy Pierce⁶, Sharon Brangman⁷, Mary Sano⁸, Jeffrey Kaye⁶, Miranda Lim⁶, Michael Au-Yeung⁶, Michelle Herman⁹, Gabriel Leger⁹, Karen Messer⁹, Howard Feldman⁹
¹VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ²VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ³Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), ⁴Department of Neurology, University of Kentucky - Lexington (United States), ⁵Department of Family and Community Medicine, UT Health San Antonio - San Antonio (United States), ⁶Department of Neurology, OHSU School of Medicine - Portland (United States), ⁷Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), ⁸Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), ⁹Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m **OC22 - Demographic Analysis of Industry Sponsored Alzheimer's Disease Trial Populations in the United States**
Stephen Peroutka¹ - ¹PPD, Part Of Thermo Fisher Scientific - Carmel, CA (United States)

3.45 p.m **OC23 - Plasma Biomarker Findings from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial**
Eric M. Reiman¹, Francisco Lopera², Silvia Rios-Romenets², Courtney Schiffman³, Derrek Hibar³, Gwendlyn Kollmorgen⁴, Margarita Giraldo², Natalia Acosta², Alejandro Espinosa², Gustavo Villegas², Claudia Muñoz², Laura Serna², Karina Herrera², Yi Su¹, Robert Alexander¹
¹Banner Alzheimer's Institute - Phoenix, Arizona (United States), ²Neurosciences Group of Antioquia, University of Antioquia - Medellín (Colombia), ³Genentech, Inc., - South San Francisco, Ca (United States), ⁴Roche Diagnostics GmbH - Mannheim (Germany)

3.50 p.m Coffee break and poster session 

4.15 p.m LATE BREAKING ORAL COMMUNICATIONS

5.00 p.m End of the Conference Day

● Friday, DECEMBER 2

- 9.00 a.m **KEYNOTE 4**
Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
Roger Nitsch, Neurimmune, Schlieren (Switzerland)
- 9.20 a.m **LATE BREAKING ORAL COMMUNICATIONS**
- 10.20 a.m Coffee break and poster session ☕
- 10.45 a.m **ROUNDTABLE 2**
The Alzheimer's disease Patient Pathway from a sex and gender lens
Chair: Frances Catherine Quevenco ^{1, 2}
Discussants: Maria Carmela Tartaglia ³, Maria Carrillo ⁴, Phyllis Ferrell ⁵, Pernille Poulsen ⁶, Antonella Santucci Chadha ^{7, 2}
¹Roche (Switzerland), ²Women's Brain Project (Switzerland), ³University Of Toronto (Canada), ⁴Alzheimer's Association (United States), ⁵Eli Lilly (United States), ⁶Novo Nordisk (Denmark), ⁷Altoia (United States)
- 11.15 a.m **ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design**
- 11.15 a.m **OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Kaya Jordan ¹, Kennedy Mahdavi ^{1, 2}, Jonathan Haroon ¹, Elisabeth Rindner ¹, Margaret Zielinski ¹, Victoria Venkatraman ^{1, 2}, Sergio Becerra ², Dayan Goodenow ³, Clarence Ahlem ⁴, Christopher Reading ⁴, Joseph Palumbo ⁴, Bijan Pourat ⁵, Sheldon Jordan ^{1, 2}
¹The Regenesis Project - Santa Monica (United States), ²Synaptec Network - Santa Monica (United States), ³Prodrome Sciences USA LLC - Temecula (United States), ⁴Biovie Inc. - Carson City (United States), ⁵Pourat MD - Beverly Hills (United States)
- 11.25 a.m **OC25 - HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer's disease with AGB101: Baseline Tau and MRI imaging characteristics**
Richard Mohs ¹, Sharon Rosenzweig-Lipson ¹, Arnold Bakker ², Elizabeth Chang ², Nisha Rani ², Russell Barton ¹, Michela Gallagher ^{1, 2}
¹AgeneBio, Inc - Baltimore (United States), ²Johns Hopkins University - Baltimore (United States)
- 11.35 a.m **OC26 - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy**
Jan Johansson ¹, Hussein Yassine ², Danny Michaelson ³, Henrik Zetterberg ⁴, Jeffrey Cummings ⁵, Bengt Winblad ⁶
¹Artery Therapeutics, Inc. - San Ramon (United States), ²USC - Los Angeles (United States), ³Tel Aviv University - Tel Aviv (Israel), ⁴U of Gothenburg - Gothenburg (Sweden), ⁵U Nevada Las Vegas - Las Vegas (United States), ⁶Karolinska Institute - Stockholm (Sweden)
- 11.45 a.m **OC27 - Effects of Oral ALZ-801 on Plasma Biomarkers and Cognition in APOE4 Carriers with Early Alzheimer's Disease: Six-month Interim Analysis from the Phase 2 Biomarker Study**
Susan Abushakra ¹, John Hey ¹, Kaj Blennow ², Philip Scheltens ³, Jakub Hort ⁴, Sheardove Katerina ⁵, Sterre Rutgers ⁶, Prins Niels ⁶, Dautzenberg Paul ⁷, Pazdera Ladislav ⁸, Power Aidan ¹, Tolar Martin ¹
¹Alzheon Inc - Framingham, Ma (United States), ²Alzheon Inc - Molndal (Sweden), ³Amsterdam University Medical Centers - Amsterdam (Netherlands), ⁴Charles University - Prague (Czech Republic), ⁵St. Anne University Hospital - Brno (Czech Republic), ⁶Brain Research Centers - Amsterdam (Netherlands), ⁷Brain Research Centers - Den Bosch (Netherlands), ⁸Vestra Clinics - Rychnov nad Kněžnou (Czech Republic)
- 11.55 a.m **ORAL COMMUNICATIONS**
- 11.55 a.m **OC28 - Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease**
Nicola Spotorno ¹, Olof Strandberg ¹, Geraline Vis ^{2, 3}, Erik Stomrud ¹, Markus Nilsson ^{2, 4}, Oskar Hansson ¹
¹Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), ²Diagnostic Radiology, Institution For Clinical Sciences, Lund University - Lund (Sweden), ³Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁴Memory Clinic, Skåne University Hospital - Malmö (Sweden)

● Friday,
DECEMBER 2



- 12.10 p.m **OC29 - A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale**
Caroline Skirrow¹, Jack Weston¹, Marton Meszaros¹, Udeepa Meepegama¹, Emil Fristed¹
¹Novoic - London (United Kingdom)
- 12.25 p.m **OC30 - A β -structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer's Disease 17 Years in Advance**
Klaus Gerwert^{1,2}
¹Ruhr-University Bochum - Bochum (Germany), ²Center for Protein Diagnostics (ProDi) - Bochum (Germany)
- 12.40 p.m Lunch break and poster sessions
- 1.30 p.m **ORAL COMMUNICATIONS' FOCUS SESSION: Clinical Trials Phase 1 Results**
- 1.30 p.m **OC31 - NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease**
Daniel Mikol¹, Judy Toews¹, Martin Farlow², Bruce Lamb², George Perry³, Reisa Sperling⁴, Michael Weiner⁵, Henrik Zetterberg⁶, Jeffrey Cummings⁷
¹Nervgen - Vancouver (Canada), ²Indiana University School Of Medicine - Indianapolis (United States), ³University Of Texas, San Antonio - San Antonio (United States), ⁴Harvard Medical School - Cambridge (United States), ⁵University Of California, San Francisco - San Francisco (United States), ⁶University Of Gothenburg - Gothenburg (Sweden), ⁷University Of Nevada, Las Vegas - Las Vegas (United States)
- 1.40 p.m **OC32 - Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP**
Peter Ljubenkov¹, Adam Staffaroni¹, Lawren Vandevrede¹, Julio Rojas-Martinez¹, Mary Koestler¹, Anton Porsteinsson², Maria B. Pascual³, Joseph Masdeu³, Ian Grant⁴, David Irwin⁵, David Knopman⁶, Robert Bowser⁷, Murray Grossman⁵, Irfan Qureshi⁸, Adam Boxer¹
¹UCSF Memory and Aging Center - San Francisco (United States), ²University of Rochester - Rochester (United States), ³Houston Methodist - Houston (United States), ⁴Northwestern University - Chicago (United States), ⁵University of Pennsylvania - Philadelphia (United States), ⁶Mayo Clinic Rochester - Rochester (United States), ⁷Barrow Neurological Institute - Phoenix (United States), ⁸Biohaven Pharmaceuticals - New Haven (United States)
- 1.50 p.m **OC33 - A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease - Interim Data**
Michael Kaplitt¹, Philip Leopold², Evan Noch³, Jana Ivanidze⁴, Levi Chazen⁴, Ronald Crystal², Stephen Kaminsky², Haley Bowe², Mei Wang², Douglas Ballon⁴, Jonathan Dyke⁴, Dolan Sondhi², Sam Gandy⁵, Gina Giannantoni-Ibelli⁶, Jay Barth⁶
¹Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), ²Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), ³Department of Neurology, Weill Cornell Medical College - New York (United States), ⁴Department of Radiology, Weill Cornell Medical College - New York (United States), ⁵Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), ⁶LEXEO Therapeutics, Inc. - New York (United States)
- 2.00 p.m **ORAL COMMUNICATIONS**
- 2.00 p.m **OC34 - Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample**
Chris Edgar¹, Rebecca Amariglio², Jordan Barbone³, Julie Chandler⁴, Stephen Coons⁵, Michael Donohue⁶, William Lenderking⁷, Reisa Sperling⁸
¹Cogstate - London (United Kingdom), ²Departments of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³Cogstate - New Haven (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Clinical Outcome Assessment Program, Critical Path Institute - Tucson (United States), ⁶Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁷Patient-centered Research, Evidera - Bethesda (United States), ⁸Department of Neurology, Brigham and Women's Hospital - Boston (United States)

● Friday, DECEMBER 2

- 2.15 p.m **OC35 - APOE-Targeted Epigenome Therapy for Alzheimer's Disease**
Boris Kantor ^{1,2}, Ornit Chiba-Falek ^{1,3}
¹Duke University - Durham (United States), ²CLAIRGene LLC - Durham (United States), ³CLAIRGene - Durham (United States)
- 2.30 p.m **OC36 - Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance**
Alexa Pichet Binette ¹, Shorena Janelidze ¹, Nicholas Cullen ¹, Jeffrey L. Dage ², Randall J. Bateman ³, Henrik Zetterberg ^{4,5}, Kaj Blennow ⁴, Erik Stomrud ¹, Niklas Mattsson-Carlgrén ¹, Oskar Hansson ¹
¹Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), ²Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), ³Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), ⁴Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁵UK Dementia Research Institute, University College London - London (United Kingdom)
- 2.45 p.m **OC37 - Aducanumab and lecanemab label insoluble, fibrillar, diffusible A β aggregates in aqueous extracts of human Alzheimer disease brain**
Andrew M. Stern ¹, Angela L. Meunier ¹, Wen Liu ¹, Maria Ericsson ², Dennis J. Selkoe ²
¹Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston (United States), ²Harvard Medical School Electron Microscopy Core - Boston (United States)
- 3.00 p.m **OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer's disease**
Jared C. Roach ¹, Lance E. Edens ¹, Sophiya Rajbhandari ¹, Junko Hara ², Jennifer Bramen ^{3,4}, Molly K. Rapozo ⁵, Cory Funk ¹, William R. Shankle ^{6,7,2,8}, Leroy Hood ¹
¹Institute For Systems Biology - Seattle, Washington (United States), ²Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), ³Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), ⁴Department of Translational Neurosciences and Neurotherapeutics, Saint John's Cancer Institute - Santa Monica, California (United States), ⁵Providence St. Joseph Health - Renton, Washington (United States), ⁶Shankle Clinic - Newport Beach, California (United States), ⁷Department of Cognitive Sciences, University of California - Irvine, California (United States), ⁸EMBIC Corporation - Newport Beach, California (United States)
- 3.15 p.m **OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer's disease**
Marija Vukicevic ¹, Emma Fiorini ¹, David Hickman ¹, Raket Carpintero ², Marcela Rincon ², Maria Pilar Lopez-Deber ², Maxime Ayer ², Stefanie Siegert ², Chiara Babolin ², Eva Gollwitzer ², Saskia Delpretti-Anex ², Piergiorgio Donati ², Johannes Streffer ^{2,3}, Andrea Pfeifer ², Marie Kosco-Vilbois ²
¹Ac Immune SA - Lausanne (Switzerland), ²Ac Immune SA - Lausanne (Switzerland), ³University of Antwerp - Antwerpen (Belgium)
- 3.30 p.m **OC40 - U-p53AZ in prognostication of early onset Alzheimer's disease up to 6 years in advance of the clinical diagnosis**
Simona Piccirella ¹, Leander Van Neste ², Christofer Fowler ³, Colin Masters ³, Jurgen Fripp ⁴, James D. Doecke ⁴, Chengjie Xiong ⁵, Daniela Uberti ⁶, Paul Kinnon ¹
¹Diadem SpA - Brescia (Italy), ²Halix BV - Hoegaarden (Belgium), ³The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), ⁴The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁵Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), ⁶Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy)
- 3.45 p.m **OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic**
Clive Ballard ¹, Joanne Mcdermid ¹, Adrienne Sweetnam ¹
¹University of Exeter - Exeter (United Kingdom)
- 4.00 p.m **OC42 - Making digital measures fit-for-purpose in Alzheimer's trials**
Francesca Cormack ¹, Jennifer Sorinas ², Claire Meunier ³
¹Cambridge Cognition - Cambridge (United Kingdom), ²Novartis - Basel (Switzerland), ³DiMe - San Francisco (United States)
- 4.15 p.m **End of the Conference Day**



POSTER PRESENTATIONS
presented in San Francisco
and available on the CTAD22
digital platform

POSTERS PRESENTATIONS

All posters are available in Pdf format
at all times on the CTAD22 digital platform.

Poster presentations presented onsite
in San Francisco are indicated with this icon : 

Tuesday, November 29 at 4 p.m to Wednesday, November 30 at 6 p.m

THEME: Clinical Trials: Methodology	P001 to P023
THEME: New Therapies and Clinical Trials	P024 to P033
THEME: Clinical Trials: Results	P034 to P049
THEME: Beyond Amyloid and Tau: Emerging Solutions	P050 to P068

Thursday, December 1st from 8 a.m to 6 p.m

THEME: Clinical Trials Imaging	P069 to P089
THEME: Clinical Trials: Biomarkers including plasma	P090 to P125
THEME: Cognitive and Functional Endpoints	P126 to P140

Friday, December 2nd from 8 a.m to 5 p.m

THEME: Cognitive assessment and clinical trials	P141 to P168
THEME: Behavioral disorders and clinical trials	P169 to P171
THEME: Health economics and clinical trials	P172 to P175
THEME: Epidemiology and clinical trials	P176 to P186
THEME: Animal Models and Clinical Trials	P187 to P190
THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions	P191 to P204
THEME: Digital health/E-trials	P205 to P222

THEME: Clinical Trials: Methodology

-  **P001** **Feasibility of virtual amyloid PET disclosure with cognitively unimpaired research participants**
Claire Erickson¹, Nathaniel Chin¹, Hannah Rosario¹, Amanda Peterson¹, Sterling Johnson¹, Lindsay Clark¹
¹University Of Wisconsin-Madison - Madison (United States)
-  **P002** **Using common-close trial designs for efficiently detecting slowing of progression in Alzheimer's disease**
Lars Lau Raket¹, Jeffrey Cummings²
¹Novo Nordisk - Søborg (Denmark), ²Chambers-Grundy Center For Transformative Neuroscience, Pam Quirk Brain Health And Biomarker Laboratory, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States)
-  **P003** **Evaluating KarXT (xanomeline-trospium) as a treatment for psychosis associated with Alzheimer's disease dementia: design of the phase 3, ADEPT-1, relapse prevention study**
Carolyn Watson¹, Jeffrey Cummings², George Grossberg³, Minsu Kang¹, Ronald Marcus¹
¹Karuna Therapeutics - Boston (United States), ²University Of Nevada Las Vegas School Of Integrated Health Sciences - Las Vegas (United States), ³Saint Louis University School Of Medicine - Saint Louis (United States)
-  **P004** **Number of Days Between Initial Contact and In-Person Visit Predict Attendance Rates for Potential Alzheimer's Disease Trial Participants**
Sarah Starling¹, Gabriela Munoz¹, Miriam Evans¹, Jenicka Engler¹, Stephanie Rutrick¹
¹Adams Clinical - Watertown (United States)
-  **P005** **Power analysis of a prognostic enrichment procedure based on AD Course Map, a simulation study**
Etienne Maheux¹, Igor Koval¹, Juliette Ortholand¹, Colin Birkenbihl², Vincent Bouteloup³, Stanley Durrleman¹
¹Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris (France), ²Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Sankt Augustin (Germany), ³Université de Bordeaux, Inserm 1219, CIC1401-EC - Bordeaux (France)
-  **P006** **Implementing Novel Clinical Trial Designs in Dementia with Lewy Bodies: A Roadmap to Personalized Medicine**
Carla Abdelnour¹, Jon B. Toledo², Daniel Ferreira³, Federico Rodríguez-Porcel⁴, Parichita Choudhury⁵, Maureen Okafor⁶, Sonja Scholz⁷, Bradley Boeve⁵, Irene Litvan⁸, James Leverenz⁹, Laura Bonanni¹⁰, John-Paul Taylor¹¹, Simon J. G. Lewis¹², Dag Aarsland¹³, Kathleen Poston¹
¹Neurology And Neurological Sciences Department, Stanford University - Palo Alto (United States), ²Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), ³Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska Institutet - Stockholm (Sweden), ⁴Department Of Neurology, Medical University Of South Carolina - Charleston (United States), ⁵Department Of Neurology, Mayo Clinic - Rochester (United States), ⁶Department Of Neurology, Emory University School Of Medicine - Atlanta (United States), ⁷Neurodegenerative Diseases Research Unit, National Institute Of Neurological Disorders And Stroke. Laboratory Of Neurogenetics, National Institute On Aging - Bethesda (United States), ⁸Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁹Lou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology, Cleveland Clinic - Cleveland (United States), ¹⁰Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara - Chieti (Italy), ¹¹Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), ¹²Forefront Parkinson's Disease Research Clinic, Brain And Mind Centre, University Of Sydney - Camperdown Nsw 2050 (Australia), ¹³Institute of Psychiatry, Psychology, & Neuroscience, King's College London - London (United Kingdom)
-  **P007** **Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is commonly misdiagnosed as Alzheimer's disease (AD) and Frontotemporal Dementia (FTD)**
Spyros Papapetropoulos¹, Angela Pontius², Samantha Zappia¹, Matthew Brennan², Leslie Leahy²
¹Vigil Neuroscience - Cambridge (United States), ²Consultant To Vigil Neuroscience - Cambridge (United States)
-  **P008** **Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCBO107, in prodromal-to-mild Alzheimer's disease**
Matthew E. Barton¹, Bart Van Den Steen², Hans L. G. Van Tricht², William Byrnes¹, Fiona E. Purcell³, Sarah Ann Southcott³, Daniel Raby³, Yaroslav I. Starshinov³, Colin Ewen²
¹UCB Pharma - Raleigh, North Carolina (United States), ²UCB Pharma - Brussels (Belgium), ³ICON plc - Dublin (Ireland)
- P009** **The impact of erratic changes on 1 year change in CDR-SB. An exploratory analysis.**
Alan Kott¹, Xingmei Wang², David Miller²
¹Signant Health - Prague (Czech Republic), ²Signant Health - Blue Bell (United States)
-  **P010** **Early Engagement with the Alzheimer's Disease Community to Gain Insights into Designing the SKYLINE Trial for Pre-symptomatic Alzheimer's Disease**
Fiona Rose¹, Nancy Lynn², Jessica B. Langbaum³, Carolyn Langlois³, Emma Louise Dodd¹, Jannice Roeser⁴, Gesine Respondek⁴, Susanne Ostrowitzki⁴
¹Roche Products Ltd - Welwyn Garden City (United Kingdom), ²BrightFocus Foundation - Clarksburg (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P011** **Contrasting the NIH Toolbox Emotional Battery Outcomes Between Caucasians and African American Older Adult Participants in a Randomized Clinical Trial: I-CONNECT Study**
Kexin Yu¹, Lisa Silbert^{1,2}, Laura Struble³, Hiroko H. Dodge¹
¹NIA-Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA - Portland (United States), ²Portland Veterans Affairs Health Care System, Portland, OR, USA - Portland (United States), ³Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan Ann Arbor, Michigan, USA - Ann Arbor (United States)

- P012** **Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection**
Dylan Kirn¹, Joshua Grill², Paul Aisen³, Karin Ernstrom³, Seth Gale⁴, Judith Heidebrink⁵, Gregory Jicha⁶, Gustavo Jimenez-Maggiora³, Leigh Johnson⁷, Elaine Peskind⁸, Raymond Scott Turner⁹, David Sultzer², Shunran Wang³, Reisa Sperling⁴, Rema Raman³
¹Department of Neurology, Massachusetts General Hospital - Boston (United States), ²Institute for Memory Impairments and Neurological Disorders, Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States), ³Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Department of Neurology, University of Michigan - Ann Arbor (United States), ⁶Sanders-Brown Center on Aging, University of Kentucky - Lexington (United States), ⁷Institute for Translational Research, University of North Texas Health Science Center - Fort Worth (United States), ⁸VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System - Seattle (United States), ⁹Department of Neurology, Georgetown University Medical Center - Washington D.c. (United States)
- P013** **Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the COcoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind)**
Mark Espeland¹, Joann Manson², Steve Rapp¹, Howard Sesso², Sarah Gaussoin¹, Sally Shumaker¹, Laura Baker¹
¹Wake Forest School of Medicine - Winston-Salem (United States), ²Brigham and Women's Hospital - Boston (United States)
- P014** **Use of the Digit Symbol Substitution Test (DSST) as an entry criterion for a cognitive study of a β 2-AR agonist.**
 Gabriel Vargas¹, Renee Martin¹, Peter Butera¹, Judy Reynolds¹, Tim Anderson², Aliya Asher³, Erik Buntinx⁴, Anthony Ford¹, John Harrison⁵
¹CuraSen - San Carlos (United States), ²New Zealand Brain Research Institute - Christchurch (New Zealand), ³MAC Clinical Research - Manchester (United Kingdom), ⁴Anima Research Center - Alken (Belgium), ⁵Metis Cognition - Kilmington Common (United Kingdom)
- P015** **Improving the accuracy and precision of Lecanemab treatment effect assessment using Alzheimer's disease prognostic covariate**
Viswanath Devanarayan¹, Liang Zhu¹, Michael Irizarry¹, Lynn Kramer¹, Shobha Dhadda¹
¹Eisai, Inc. - Nutley (United States)
- P016** **Enhancing Recruitment of Underrepresented Communities with the Deployment of a Mobile Research Unit**
Jill Smith¹, John Dwyer¹, Dawn Batchuluun¹, Tamiko Magee Rodgers¹, Leigh Zisko¹
¹Global Alzheimer's Platform Foundation - Washington Dc (United States)
- P017** **Genotypic effects of the TOMM40'523 variant and APOE on longitudinal cognitive change over 4 years: The TOMMORROW Study**
 Haotian Zou¹, Sheng Luo², Michael W. Lutz², David A. Bennett³, Brenda L. Plassman², Kathleen A. Welsh-Bohmer²
¹University of North Carolina- Chapel Hill - Chapel Hill (United States), ²Duke University - Durham (United States), ³Rush University - Chicago (United States)
- P018** **Racial/ethnic Group Differences in Response Rate to a Mail Invitation to Participate in a Lifestyle Intervention Trial to Prevent Cognitive Decline (U.S. POINTER Trial)**
Valory Pavlik¹, Melissa Yu¹, Ashley Alexander², John Valenta², Richard Elbein³, Annmarie McDonald³
¹Baylor College Of Medicine - Houston (United States), ²Kelsey Research Foundation - Houston (United States), ³Alzheimer's Association - Houston (United States)
- P019** **Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials**
Abigail O Connell¹, Eric Fischer¹, Lauren Latham¹, Laura Baker¹, Suzanne Craft¹
¹Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)
- P020** TBD
- P021** **Using an end-to-end deep learning model in older adults with MCI to identify AD risk factors on chromosome 19 that exacerbate cognitive decline**
Jinhyeong Bae¹, Liana Apostolova¹, Valentin Pentchev¹, Dustin Hammers¹, Angelina Polsinelli¹, Kelly Nudelman¹, Andrew Saykin¹, Kwangsik Nho¹
¹IUPUI - Indianapolis (United States)
- P022** **Pandemic Effects on Duplicate Subjects in Clinical Trials of Alzheimer's Disease**
Thomas Shiovitz¹, Chelsea Steinmetz², Brittany Steinmiller²
¹California Neuroscience Research, CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands), ²CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands)
- P023** **The Time Component Test is Inherently Meaningful Because it Combines Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases**
Samuel Dickson¹, Suzanne Hendrix¹
¹Pentara Corporation - Salt Lake City (United States)

THEME: New Therapies and Clinical Trials

-  **P024** **Potential Reversal of Alzheimer's Disease pathology by Antibody TB006 Targeting Galectin-3, a Major Cause of Oligomerization of Amyloid Proteins**
Suhail Rasool¹, Jenny Johansson¹, Ludmila Voloboueva¹, Sangmi Lee¹, Nancy Lan¹, Taufeeq Ahmed¹, Dongxu Sun¹
¹Truebinding Inc. - Foster City (United States)
-  **P025** **Whole-Brain Low-Intensity Pulsed Ultrasound Therapy For Early Stage Of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial**
Hiroaki Shimokawa^{1,2}, Tomohiko Shindo¹, Aiko Ishiki³, Naoki Tomita³, Kumiko Eguchi¹, Takashi Shiroto¹, Jun Takahashi¹, Kentaro Shiratsuchi⁴, Satoshi Yasuda¹, Hiroyuki Arai³
¹Tohoku University Graduate School Of Medicine - Sendai (Japan), ²International University of Health and Welfare - Narita (Japan), ³Institute Of Development, Aging And Cancer, Tohoku University - Sendai (Japan), ⁴Sound Wave Innovation, Co. - Tokyo (Japan)
-  **P026** **CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer's disease**
 Alan Lerner^{1,2}, Steven Arnold³, Erin Maxfield⁴, Aaron Koenig³, Maria Toth¹, Brooke Fortin³, Bianca Trombetta³, Andrew Pieper^{5,6,7,8}, Curtis Tatsuoka⁹, Irina Pikuleva⁴
¹Brain Health And Memory Center, Neurological Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), ²Department of Neurology, Case Western Reserve University - Cleveland (United States), ³Alzheimer's Clinical And Translational Research Unit, Massachusetts General Hospital - Boston (United States), ⁴Department Of Ophthalmology And Visual Sciences, Case Western Reserve University - Cleveland (United States), ⁵Harrington Discovery Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), ⁶Department Of Psychiatry, Case Western Reserve University - Cleveland (United States), ⁷Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center - Cleveland (United States), ⁸Institute For Transformative Molecular Medicine, Case Western Reserve University - Cleveland (United States), ⁹Department Of Population And Quantitative Health Sciences, Case Western Reserve University - Cleveland (United States)
-  **P027** **A Phase 2 Study of the Sigma-2 Ligand CT1812 in Participants with Dementia with Lewy Bodies**
James Galvin¹, Magdalena Tolea¹, Michael Grundman², Mary Hamby³, Anthony Caggiano⁴
¹Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, FL (United States), ²Grnd Partners - San Diego, Ca (United States), ³Cognition Therapeutics - Pittsburgh, Pa (United States), ⁴Cognition Therapeutics - Purchase, Ny (United States)
-  **P028** **ALZLIGHT Pilot: Preliminary Report on Safety and Feasibility From a Randomized Controlled Trial of Light-Based Brain Stimulation With 40 Hz Invisible Spectral Flickering Light in Patients With Mild-to-Moderate Alzheimer's Disease**
Mikkel Pejstrup Agger^{1,2}, Marcus Schultz Carstensen³, Maibritt Homing^{1,2}, Else Rubæk Danielsen⁴, Anders Ohlhues Baandrup⁴, Mai Nguyen⁵, Mark Alexander Henney⁵, Christopher Ravn Boe Jensen⁵, Kristoffer Hougaard Madsen^{6,7}, Troels Wesenberg Kjær^{1,2}, Kamilla Miskowiak^{8,9}, Paul Michael Petersen³, Peter Høgh^{1,2}
¹Department of Neurology, Zealand University Hospital - Roskilde (Denmark), ²Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ³Dept. of Electrical and Photonics Engineering, Technical University of Denmark - Kgs. Lyngby (Denmark), ⁴Department of Radiology, Zealand University Hospital - Roskilde (Denmark), ⁵OptoCeutics ApS - Copenhagen (Denmark), ⁶Dept. of Applied Mathematics and Computer Science, Technical University of Denmark - Copenhagen (Denmark), ⁷Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital - Amager and Hvidovre - Copenhagen (Denmark), ⁸Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen - Copenhagen (Denmark), ⁹Department of Psychology, University of Copenhagen - Copenhagen (Denmark)
-  **P029** **Characterization of amyloid-beta protofibrils in Alzheimer's disease brain and the unique binding properties of lecanemab**
Lars Lannfelt¹, Linda Söderberg¹, Malin Johannesson¹, Nicolas Fritz¹, Eleni Gkanatsiou¹, Adeline Rachalski¹, Helen Kylefjord¹, Gunilla Osswald¹, Christer Möller¹
¹BioArctic AB - Stockholm (Sweden)
-  **P030** **AD101 - the clinical profile of a new, first-in-class treatment for Alzheimer's Disease**
Jan Burmeister¹, Serge Gauthier², Sharon Rogers¹
¹Amyriad Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)
-  **P031** **Impact of pimavanserin on cognitive measures in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 placebo-controlled clinical studies**
Clive Ballard¹, Victor Ablter², Sanjeev Pathak², Pierre Tariot¹, Bruce Coate², Ana Berrio², James M Youakim², Srdjan Stankovic²
¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ²ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P032** **Impact of pimavanserin treatment on motor function in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 clinical studies**
 Daniel Weintraub¹, Victor Ablter², Clive Ballard¹, Bruce Coate², Ana Berrio², Sanjeev Pathak², James M Youakim², Srdjan Stankovic²
¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ²ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P033** **Intravenous treatment with BRICHOS molecular chaperone designed against amyloid-β toxicity improves features of Alzheimer disease pathology in mice**
Jan Johansson¹
¹Karolinska Institutet - Huddinge (Sweden)

THEME: Clinical Trials: Results

-  **P034** **Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Elisabeth Rindner¹, Kennedy Mahdavi^{1,2}, Jonathan Haroon¹, Kaya Jordan¹, Margaret Zielinski¹, Victoria Venkatraman^{1,3}, Dayan Goodenowe⁴, Clarence Ahlem⁵, Christopher Reading⁵, Joseph Palumbo⁵, Bijan Pourat⁶, Sheldon Jordan^{1,3}
¹The Regenesys Project - Santa Monica (United States), ²Synaptec Network, - Santa Monica (United States), ³Synaptec Network - Santa Monica (United States), ⁴Prodrome Sciences USA LLC - Temecula (United States), ⁵Biovie Inc. - Carson City (United States), ⁶Pourat MD - Beverly Hills (United States)
-  **P035** **Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer's disease: a significant clinical effect but a low benefit/risk ratio**
Nicolas Villain¹, Vincent Planche²
¹Ap-Hp Sorbonne Université, Hôpital Pitié-Salpêtrière, Department Of Neurology, Institute Of Memory And Alzheimer's Disease - Paris (France), ²Univ. Bordeaux, Cnrs, Imn, Umr 5293 - Bordeaux (France)
-  **P036** **LilyPADD Trial: Targeting Hippocampal Hyperconnectivity in Cognitively Normal Older Adults at Risk for Alzheimer's Disease with AGB101**
 Shi-Jiang Li¹, Arnold Bakker², Yang Wang¹, B. Doug Ward¹, Shelby Schold¹, Piero Antuono¹, E. G. Deluque¹, Malgorzata Franczak¹, Joseph Goveas¹
¹Medical College Of Wisconsin, ²Johns Hopkins University
-  **P037** **Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Zihan Cui¹, Eileen Priest¹, Corissa Lau¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States)
-  **P038** **Critical Path for Alzheimer's Disease (CPAD) Consortium: Accelerating and de-risking therapeutic development in AD by building regulatory decision-making tools**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Corissa Lau¹, Eileen Priest¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai - Nutley (United States)
-  **P039** **Effectiveness of a digitally supported care management program for family and other informal dementia caregivers: baseline data and first results from the GAIN randomized**
Ingo Kilimann¹, Olga Klein², Jochen René Thyrian³, Melanie Boekholt³, Stefan Teipel¹, Wolfgang Hoffmann⁴
¹Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald And University Medical Center Rostock, Department Psychosomatics And Psychotherapy - Rostock (Germany), ²Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald - Rostock (Germany), ³Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald - Greifswald (Germany), ⁴Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald And University Hospital Greifswald, Institute For Community Medicine - Greifswald (Germany)
-  **P040** **Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101**
Michael Ward¹, Felix Yeh¹, Daniel Maslyar¹, Yijie Liao¹, Hua Long¹, Hernan Picard¹, Michael Kurnellas¹, Mayura Vadhavkar¹, Amber Silva¹
¹Alector, Inc. - South San Francisco (United States)
-  **P041** **SAL-AD: A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease**
Peter Ljubenkov¹, Lauren Vandevrede¹, Rojas Rojas¹, Madison Honey², Argentina Lario Lago¹, Richard Tsai³, Mary Koestler¹, Renaud La Joie¹, Keith Alan Johnson⁴, Li Gan⁵, Stephanie Lessig⁶, James Brewer⁶, Howard Feldman⁶, Charlotte Teunissen⁷, Adam Boxer¹
¹UCSF Memory and Aging Center - San Francisco (United States), ²Amsterdam UMC - Amsterdam (Netherlands), ³Denali Therapeutics - San Francisco (United States), ⁴Harvard Medical School - Boston (United States), ⁵Weill Cornell Medical College - New York (United States), ⁶UC San Diego - San Diego (United States), ⁷Amsterdam UMC - Amsterdam (United States)
-  **P042** **Early experience with home administration of subcutaneous gantenerumab by study partner (non-professional care partner) in the GRADUATION study**
Richard Perry¹, Frank Boess², Marzia Scelsi³, Timo Grimmer⁴, Rafael Arroyo⁵, Christopher Lane³, Claire Lansdall², Janice Smith³
¹Imperial College London - London (United Kingdom), ²F. Hoffmann-La Roche Ltd - Basel (Switzerland), ³Roche Products Ltd - Welwyn Garden City (United Kingdom), ⁴Klinikum rechts der Isar, Technical University of Munich - Munich (Germany), ⁵Quirónsalud Madrid University Hospital - Madrid (Spain)
-  **P043** **A Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI-002 in MCI and mild AD**
Oliver Peters¹, Nicoleta-Carmen Cosma¹, Janine Kutzsche¹, Dieter Willbold¹
¹Charité - Berlin (Germany)
-  **P044** **Enabling subcutaneous dosing of gantenerumab in Alzheimer's Disease**
Beate Bittner¹, Dietmar Schwab¹, Agnes Portron¹, Dominik Lott¹, Frank Boess¹, Rémy Kohler¹, Jakub Wojtowicz¹, Carsten Hofmann¹
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P045** **The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Primary Analyses Results**
Hiroko Dodge¹, Patrick Pruiitt¹, Xexin Yu¹, Chao-Yi Wu¹, Jeffrey Kaye¹, Lisa Silbert¹, I-Conect Conect-Team¹
¹Oregon Health & Science University - Portland (United States)

- 
P046 **Computerized Games versus Crosswords Training in Mild Cognitive Impairment**
Davangere Devanand¹, Terry Goldberg¹, Min Qian¹, Murali Doraiswamy²
¹Columbia University Medical Center - New York (United States), ²Duke University - Durham (United States)
- 
P047 **Pimavanserin and cardiovascular/electrocardiogram safety in patients with Alzheimer's disease**
Pierre Tariot¹, Victor Abler², Sanjeev Pathak², Bruce Coate², Mary Ellen Turner²
¹Banner Alzheimer's Institute and University of Arizona College of Medicine - Phoenix, Az (United States), ²Acadia Pharmaceuticals Inc. - San Diego, Ca (United States)
- 
P048 **The effects of the novel phosphodiesterase 9 (PDE9) inhibitor E2027 (irsenontrine) on CSF cGMP, additional CSF and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD)**
Pallavi Sachdev¹, Kate Pinner², Theresa Devins¹, Larisa Reyderman¹, David Li¹, Shobha Dhadha¹, Lynn Kramer¹, Akihiko Koyama¹, Michael Irizarry¹, Steven Hersch¹
¹Eisai Inc. - Nutley (United States), ²Eisai Ltd. - Hattfield (United Kingdom)
- 
P049 **Clinical Activity of the p38 α kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB)**
John Alam¹, Jennifer Conway¹, Hui-May Chu², Kelly Blackburn¹
¹EIP Pharma, Inc - Boston (United States), ²Anoixis Corporation - Natick (United States)

THEME: Beyond Amyloid and Tau: Emerging Solutions

- 
P050 **TBA**
- 
P051 **Improvement of cognitive dysfunction following repeated infusion of adipose tissue-derived stem cells**
Kazuo Shigematu¹, Mitsuko Ideno², Noyuki Komori³, Hisakazu Yamagishi⁴
¹Minami Kyoto Hospital - Joyo (Japan), ²Takara Bio Inc. - Kyoto (Japan), ³Nagitsuji Hospital - Kyoto (Japan), ⁴Kyoto Prefectural University Of Medicine - Kyoto (Japan)
- 
P052 **Novel application of deep canonical correlation analysis identifies regional brain atrophy linked to proinflammatory gut microbial genera before cognitive decline**
Margo Heston^{1,2}, Zihang Meng³, Akshay Kohli^{1,2}, Antonio González⁴, Sterling Johnson^{1,2,5}, Rob Knight^{4,6,7,8}, Rima Kaddurah-Daouk^{9,10,11,12}, Federico Rey¹³, Vikas Singh^{3,14,15}, Barbara Bendlin^{1,2,5}
¹Wisconsin Alzheimer's Disease Research Center - Madison (United States), ²Division of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States), ³Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison - Madison (United States), ⁴Department of Pediatrics, University of California, San Diego - La Jolla (United States), ⁵Wisconsin Alzheimer's Institute - Madison (United States), ⁶Department of Bioengineering, University of California, San Diego - La Jolla (United States), ⁷Department of Computer Science & Engineering, University of California, San Diego - La Jolla (United States), ⁸Center for Microbiome Innovation, University of California, San Diego - La Jolla (United States), ⁹Department of Psychiatry and Behavioral Sciences, Duke University - Durham (United States), ¹⁰Department of Medicine, Duke University - Durham (United States), ¹¹Duke Institute of Brain Sciences, Duke University - Durham (United States), ¹²Duke University Medical Center - Durham (United States), ¹³Department of Bacteriology, University of Wisconsin - Madison (United States), ¹⁴Department of Computer Sciences, University of Wisconsin-Madison - Madison (United States), ¹⁵Department of Statistics, University of Wisconsin-Madison - Madison (United States)
- 
P053 **Beyond targeting Ab and tau: Novel formulations of alpha-cyclodextrins for the safe (not ototoxic) and convenient (oral) Prevention and Treatment of Alzheimer's Disease**
Knut Wittkowski¹
¹Asdera Llc - New York (United States)
- 
P054 **Lomecel-B as a Geroscience Therapeutic Candidate for Dementia and Frailty**
Anthony Oliva¹, Kevin Ramdas¹, Lisa McClain-Moss¹, Dan Gincel¹, Danial Mehranfarid¹, K. Chris Min¹, Joshua Hare¹
¹Longeveron Inc. - Miami (United States)
- 
P055 **Community Based Options to Screen for Clinical Trial Eligibility: Experience and data from the African American Fighting Alzheimer's in Mid-Life (AA-FAIM) Study**
Carey E. Gleason^{1,2}, Dorothy Farrar Edwards^{1,3}, Diane C. Gooding⁴, Gina Green Harris^{5,6}, Nathaniel A. Chin^{1,2}, Cynthia M. Carlsson^{1,7}, Maria Mora Pinzon^{7,1}, Melissa F. Metoxen⁸, Shenikqua Bouges^{1,9}, Fabu P. Carter^{1,2}, Megan Zuelsdorff^{10,2}, Rebecca Langhough Kosciak⁷, Hector Salazar¹, Nia C. Norris^{7,5}, Derek L. Norton¹¹
¹Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States), ²Wisconsin Alzheimer's Disease Research Center - Madison (United States), ³Wisconsin Alzheimer's Disease Research Center - Madison (United States), ⁴Department of Psychology, University of Wisconsin - Madison (United States), ⁵Center for Community Engagement and Health Partnerships - Milwaukee (United States), ⁶Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health - Madison (United States), ⁷Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health - Madison (United States), ⁸Native American Center for Health Professions, University of Wisconsin School of Medicine and Public Health - Madison (United States), ⁹Madison VA GRECC, William S. Middleton Memorial Hospital - Madison (United States), ¹⁰School of Nursing, University of Wisconsin - Madison (United States), ¹¹Department of Biostatistics and Medical Informatics University of Wisconsin - Madison (United States)





- P056** **The Gut-PRO Study: A Pilot Probiotic Intervention Study in Alzheimer's Disease**
Jea Woo Kang¹, Sandra J. Harding¹, Margo Heston¹, Alfred Eiji s Braceros¹, Nancy Davenport-Sis¹, Nathaniel Chin¹, Henrik Zetterberg², Federico Rey¹, Barbara b Bendlin¹
¹University of Wisconsin-Madison - Madison (United States), ²University of Gothenburg, Sahlgrenska University Hospital - Mölndal (Sweden)
- P057** TBD
- P058** **Blood levels of memory CD8 T cells that induce AD-like pathology in mice correlate with cognition and decreased CSF Abeta42 and increased CSF Tau, and accurately track AD in human patients**
Christopher Wheeler¹, Van Dam Debby², Vermeiren Yannick², De Reu Hans², De Deyn Peter Paul³
¹T-Neuro Pharma - Aptos (United States), ²University of Antwerp - Antwerp (Belgium), ³University of Groningen - Groningen (Netherlands)
- P059** **Effects of non-invasive brain stimulation on individual alpha power**
Oezguer A. Onur¹, Ronja Fassbender¹
¹Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany - Cologne (Germany)
- P060** **A pragmatic assessment of ultra-fast MRI in real-life clinical and research cognitive practice**
Miguel Rosa-Grilo¹, Eoin Mulroy¹, Millie Beament¹, Haroon Chughtai², Dave Thomas¹, Geoff Parker², Nick Fox¹, Catherine Mummery¹
¹UK Dementia Research Centre at University College London (UCL) - London (United Kingdom), ²Centre for Medical Image Computing, Department of Medical Physics & Biomedical Engineering and Department of Neuroinflammation at University College London (UCL) - London (United Kingdom)
- P061** **Optimal conditions for entraining gamma waves using sensory stimulation in older adults**
Yeseung Park¹, Euisuk Yoon¹, Ki Woong Kim¹
¹Seoul National University - Seoul (Korea, Republic of)
- P062** **Serum levels of glycan epitope correlate with tau and predict progression to dementia in combination with APOE4 allele status**
Robin Ziyue Zhou¹, Davide Liborio Vetrano², Giulia Grande², Bengt Winblad¹, Lars Tjernberg¹, Sophia Schedin-Weiss¹
¹Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet - Solna (Sweden), ²Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University - Stockholm (Sweden)
- P063** **Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study**
Anna Matton¹, Krister Håkansson¹, Julen Goicolea¹, Makrina Daniilidou¹, Tiia Ngandu², Gorka Gerenu¹, Alina Solomon³, Hilikka Soininen³, Tiina Laatikainen², Miia Kivipelto¹
¹Karolinska Institutet - Solna (Sweden), ²Finnish Institute on Health and Welfare - Helsinki (Finland), ³University of Eastern Finland - Kuopio (Finland)
- P064** **Evaluation of long-term safety and compliance to a multinutrient intervention for up to 8 years in mild cognitive impairment / prodromal Alzheimer's disease: data from the randomised controlled LipiDiet trial**
Tobias Hartmann^{1,2}, Alina Solomon^{3,4,5}, Pieter Visser^{6,7}, Kai Blennow^{8,9}, Miia Kivipelto^{10,11,5}, Hilikka Soininen^{12,10}
¹Deutsches Institut für Demenzprävention, Saarland University - Homburg (Germany), ²Experimental Neurology - Homburg (Germany), ³Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), ⁴Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), ⁵Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), ⁶Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), ⁷Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), ⁸Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), ⁹Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, - Mölndal (Sweden), ¹⁰Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), ¹¹Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), ¹²Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)
- P065** **Method for the detection of Alzheimer's disease-specific proteins in nasal secretion**
Timo Grimmer¹, Hilary Wunderlich², Marion San Nicolás², Patrick Sommer¹, Oliver Goldhardt¹, Arno Schaepe², Klaus Hallermayer², Harald Waltenberger³, Sabine Mertzig², Thomas Heydler², Mareike Haack²
¹Technical University of Munich, School of Medicine, Klinikum rechts der Isar - Munich (Germany), ²Noselab GmbH - Munich (Germany), ³Microcoat Biotechnologie GmbH - Munich (Germany)
- P066** **Clinical utility of non-invasive whole transcriptomic profiling of Alzheimer's disease**
 Shusuke Toden¹, Jiali Zhuang¹, Stephen Quake², Robert Rissman³, James Brewer³, John Sninsky¹
¹Molecular Stethoscope - South San Francisco (United States), ²Stanford University - Stanford (United States), ³University of California, San Diego - San Diego (United States)
- P067** **Development of a selective estrogen β -receptor phytoestrogen formulation - PhytoSERM - for improving cognitive health to reduce Alzheimer's risk and menopausal symptoms: A Phase 2 randomized clinical trial**
 Claudia Lopez¹, Mark Drew¹, Gerson Hernandez¹, Roberta Brinton¹
¹University of Arizona - Tucson (United States)
- P068** **Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer's Disease Risk in Older African Americans**
 Mark Gluck¹, Bernadette Fausto¹
¹Rutgers University-Newark - Newark, Nj (United States)

THEME: Clinical Trials Imaging

-  **P069** **Do the radiomics or structural and functional magnetic resonance imaging give additional information to predict brain amyloid positivity?**
Yoojin Lee¹, Sungyang Jo¹, Jae-Hong Lee¹
¹Asan Medical Center - Seoul (Korea, Republic of)
-  **P070** **Differential effects of cardiometabolic syndrome on brain age in relation to sex and ethnicity**
Sung Hoon Kang¹, Mengting Liu², Sang Won Seo³, Hosung Kim²
¹Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), ²Usc Steven Neuroimaging And Informatics Institute, Keck School Of Medicine Of University Of Southern California - Los Angeles (United States), ³Departments Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
- P071** **Genome-Wide Association Study of the functional brain network for Alzheimer's Disease**
Minji Kim¹, Jong-Min Lee²
¹Department Of Electronic Engineering, Hanyang University - Seoul (Korea, Republic of), ²Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)
- P072** **Cerebral small vessel disease burden predicts neurodegeneration and clinical progression in nondemented elderly**
 Jin-Tai Yu¹, Lan Tan²
¹Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China), ²Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)
-  **P073** **Association of regional amyloid burden and brain volume with cognitive performances among individuals with subjective cognitive decline**
Chonghwee Lee¹, Dong Won Yang¹, Yun Jeong Hong², Seonghee Ho³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁷, Seong Hye Choi⁸, Sanggyu Lee⁹
¹Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ²Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Uijeongbu (Korea, Republic of), ³Neurology, Changwon Hanmaeum Hospital - Changwon (Korea, Republic of), ⁴Neurology, Womans University School Of Medicine, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), ⁵Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Neurology, Roa Clinic - Seongnam (Korea, Republic of), ⁸Neurology, Inha University School Of Medicine, Inha University Hospital - Incheon (Korea, Republic of), ⁹Neolab Convergence Inc. - Seoul (Korea, Republic of)
-  **P074** **The role of subthreshold levels of amyloid deposition on dementia conversion-validated with ADNI**
Hyung-Ji Kim¹, Jae-Hong Lee²
¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)
- P075** **Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer's disease**
 Etienne Bories¹, Arthur Bezie¹, Didier Cassereau¹, Julie Rachline¹, Iyed Trimeche¹, Jean-Baptiste Martini¹, Vincent Perlberg¹
¹BRAINTALE SAS - Strasbourg (France)
-  **P076** **Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer's Disease spectrum**
Xiao Da¹, Evan Hempel¹, Holly Mrozak¹, Zach Malchano¹, Brent Vaughan¹, J. Thomas Megerian¹, Mihaly Hajos^{1,2}, Aylin Cimenser¹
¹Cognito Therapeutics - Cambridge, Ma (United States), ²Yale University School of Medicine - New Haven, Ct (United States)
-  **P077** **Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward**
Luc Bracoud¹, Joonmi Oh², Qui Cao², Chris Conklin³, Madhura Ingalthalakar³, Ha Pham², David Scott², Joyce Suhy²
¹Clario (formerly Bioclinica) - Lyon (France), ²Clario (formerly Bioclinica) - San Mateo (United States), ³Clario (formerly Bioclinica) - Princeton (United States)
- P078** **Amyloid-based disease models for clinical endpoint prediction in Alzheimer's disease**
 Luis Peraza¹, Richard Joules¹, Robin Wolz¹
¹IXICO - London (United Kingdom)
-  **P079** **Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism**
 Byong Seok Ye¹, Sungwoo Kang²
¹MD. PhD - Seoul (Korea, Republic of), ²MD - Seoul (Korea, Republic of)
-  **P080** **REducing Sleep Apnoea for the PrEvention of Dementia (RESHAPED): The protocol of a multi-site feasibility randomised controlled trial**
Sharon Naismith¹, Camilla Hoyos¹, Craig Phillips¹, Yaffe Kristine², Ralph Martins³, Nathaniel Marshall¹, Jim Lagopoulos⁴, Melinda Jackson⁵, Loren Mowszowski¹, Ronald Grunstein¹
¹University of Sydney - Sydney (Australia), ²University of California - San Francisco (United States), ³University of Macquarie - Sydney (Australia), ⁴University of Sunshine Coast - Sunshine Coast (Australia), ⁵Monash University - Melbourne (Australia)
-  **P081** **Arterial stiffness is associated with cortical tau burden**
Young Noh¹
¹Gachon University Gil Medical Center - Incheon (Korea, Republic of)

-  **P082** **Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer's disease**
Richard Joules ¹, [Robin Wolz](#) ¹
¹*IXICO - London (United Kingdom)*
- P082bis** **Amyloid PET centiloid: impact of calibration and processing steps**
Luca Prosetto ¹, Mahnaz Shekari ², Lyduine E. Collij ³, Richard Manber ¹, David Vallez Garca ³, Juan Domingo Gispert Lopez ², [Robin Wolz](#) ¹
¹*IXICO - London (United Kingdom)*, ²*BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation - Barcelona (Spain)*, ³*Amsterdam UMC - Amsterdam (Netherlands)*
-  **P083** **Long-term progression of amyloid (A) and tau (T) image-based biomarker in Alzheimer's disease spectrum**
[Han-Kyeol Kim](#) ¹, Hanna Cho ¹, Jae Hoon Lee ², Young Hoon Ryu ², Chul Hyoung Lyoo ¹
¹*Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of)*, ²*Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of)*
-  **P084** **Independent effects of hippocampal subfield volumes and p-tau on memory performance in clinically unimpaired older adults**
[Tammy Tran](#) ¹, Alexandra Trelle ¹, Wilson Edward ¹, Gayle Deutsch ¹, Sharon Sha ¹, Katrin Andreasson ¹, Valerie Carr ¹, Geoffrey Kerchner ¹, Elizabeth Mormino ¹, Anthony Wagner ¹
¹*Stanford University - Stanford (United States)*
-  **P085** **Supporting the Communication of Modern Alzheimer's Data through Augmented Reality and Web Technologies**
[Tyler Ard](#) ¹, Bienkowski Michael ¹, Arthur Toga ¹
¹*USC Stevens Neuroimaging and Informatics Institute - Los Angeles (United States)*
-  **P086** **Longitudinal assessment of novel imaging markers of neuroinflammation, axonal density and demyelination as biomarkers in Alzheimer's Disease**
Maggie Roy ¹, [Jean-Rene Belanger](#) ¹, Matthieu Dumont ¹, Jean-Christophe Houde ¹, Maxime Descoteaux ¹
¹*Imeka - Sherbrooke (Canada)*
-  **P087** **Predicting PET-determined ATN biomarker status in Alzheimer's disease with MRI using deep convolutional neural networks**
[Christopher Lew](#) ¹, Longfei Zhou ¹, Maciej Mazurowski ¹, P Murali Doraiswamy ¹, Susan Landau ², Jeffrey Petrella ³
¹*Duke University Medical Center - Durham (United States)*, ²*University of California, Berkeley - Berkeley (United States)*, ³*Duke University Medical Center - Durham (United States)*
-  **P088** **Early [18F]-PI-2620 tau PET signal in the stages preceding AD dementia**
[Christina Young](#) ¹, Hillary Vossler ¹, Edward Wilson ¹, Alexandra Trelle ², Kathleen Poston ¹, Michael Zeineh ¹, Michael Greicius ¹, Greg Zaharchuk ¹, Victor Henderson ¹, Anthony Wagner ², Katrin Andreasson ¹, Guido Davidzon ¹, Elizabeth Mormino ¹
¹*Stanford ADRC - Stanford (United States)*, ²*Stanford Department of Psychology - Stanford (United States)*
-  **P089** **Amyloid and tau burden in an at-risk, cognitively unimpaired clinical trial cohort: Neuroimaging data from the U.S. POINTER trial**
[Alice Murphy](#) ¹, Theresa Harrison ¹, Tyler Ward ¹, Prashanthi Vemuri ², Robert Koeppe ³, Samuel Lockhart ⁴, Mark Espeland ⁴, Danielle Harvey ⁵, Joseph Masdeu ⁶, Hwamee Oh ⁷, Darren Gitelman ⁸, Neelum Aggarwal ⁹, Laura Baker ⁴, Charles Decarli ⁵, Susan Landau ¹
¹*U.C. Berkeley (United States)*, ²*Mayo Clinic (United States)*, ³*University of Michigan (United States)*, ⁴*Wake Forest School of Medicine (United States)*, ⁵*U.C. Davis (United States)*, ⁶*Houston Methodist (United States)*, ⁷*Brown University (United States)*, ⁸*Advocate Lutheran General Hospital (United States)*, ⁹*Rush University Medical Center (United States)*

THEME: Clinical Trials: Biomarkers including plasma

-  **P090** **Impacts of amyloid burden on longitudinal cognitive declines in subjective cognitive decline: a prospective cohort study**
[Yun Jeong Hong](#) ¹, Dong Won Yang ², Seonghee Ho ², Kwonoh Park ³, Jee Hyang Jeong ⁴, Kee Hyung Park ⁵, Sangyun Kim ⁶, Min Jeong Wang ⁶, Seong Hye Choi ⁷, Sanggyu Lee ⁸
¹*Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of)*, ²*Seoul St. Mary's Hospital - Seoul (Korea, Republic of)*, ³*Pusan National University Yangsan Hospital - Yangsan (Korea, Republic of)*, ⁴*Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of)*, ⁵*Gachon University Gil Hospital - Incheon (Korea, Republic of)*, ⁶*Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of)*, ⁷*Inha University School Of Medicine - Incheon (Korea, Republic of)*, ⁸*Neolab Convergence Inc. - Seoul (Korea, Republic of)*
-  **P091** **Predictive value of plasma p-tau181 versus baseline amyloid-PET for longitudinal amyloid accumulation in asymptomatic Alzheimer's Disease**
[Rik Vandenbergh](#) ¹, Steffi De Meyer ¹, Emma Luckett ¹, Jeroen Vanbrabant ², Jolien Schaevebeke ¹, Mariska Reinartz ¹, Isabelle Cleynen ³, Erik Stoops ², Eugene Vanmechelen ², Koen Van Laere ⁴
¹*Alzheimer Research Centre Ku Leuven, Leuven Brain Institute - Leuven (Belgium)*, ²*Adx Neurosciences - Zwijnaarde (Belgium)*, ³*Laboratory For Complex Genetics - Leuven (Belgium)*, ⁴*Nuclear Medicine Service, University Hospitals Leuven - Leuven (Belgium)*
-  **P092** **Blood biomarkers for Alzheimer's disease to predict dementia risk in a large clinic-based cohort: implications for clinical trials**
[Vincent Planche](#) ¹, Vincent Bouteloup ¹, Genevieve Chene ¹, Carole Dufouil ¹
¹*Bordeaux University - Bordeaux (France)*
-  **P093** **Independent Effect of Body Mass Index Variation on Amyloid-β Positivity**
[Sung Hoon Kang](#) ¹, Jong Hyuk Kim ², Kyunga Kim ², Sang Won Seo ³
¹*Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of)*, ²*Department Of Digital Health, Saihst, Sungkyunkwan University - Seoul (Korea, Republic of)*, ³*Department Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)*

-  **P094** Phase 2 study reveals an adequate PK/PD relationship of bosutinib in Dementia with Lewy Bodies and clears the path for larger Phase 2/3 investigations
Charbel Moussa¹, Fernando Pagan², Torres-Yaghi Yasar², Hebron Michaleine¹, Turner Raymond S¹, Ahn Jaeil¹
¹Georgetown University Medical Center - Washington (United States), ²Medstar Georgetown Hospital - Washington (United States)
-  **P095** Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Jonathan Haroon¹, Kennedy Mahdavi^{1,2}, Kaya Jordan¹, Elisabeth Rindner¹, Margaret Zielinski¹, Victoria Venkatraman^{1,2}, Dayan Goodenowe³, Kaitlyn Hofmeister³, Clarence Ahlem⁴, Christopher Reading⁴, Joseph Palumbo⁴, Bijan Pourat⁵, Sheldon Jordan^{1,2}
¹The Regenesys Project - Santa Monica (United States), ²Synaptec Network - Santa Monica (United States), ³Prodrome Sciences USA LLC - Temecula (United States), ⁴Biovie Inc. - Carson City (United States), ⁵Pourat MD - Beverly Hills (United States)
- P096** Robustness of cerebrospinal fluid (CSF) amyloid- β 1-42/amyloid- β 1-40 (A β 42/A β 40) and phosphorylated tau/amyloid- β 1-42 (pTau/A β 42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use
Chad Logan¹, Henrik Schinke¹, Christina Rabe², Maryline Simon³, Oskar Hansson^{4,5}, Kaj Blennow^{6,7}, Erik Stomrud^{4,5}
¹Roche Diagnostics GmbH - Penzberg (Germany), ²Genentech, Inc., - South San Francisco (United States), ³Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ⁴Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), ⁷Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden)
- P097** The biomarker-based etiological diagnosis of neurocognitive disorders: the European Inter-Societal Delphi Consensus
Stefania Orini^{1,2}, Cristina Festari³, Federico Massa⁴, Matteo Cotta Ramosino^{5,6}, Flavio Nobili^{7,8}, Giovanni Battista Frisoni^{9,10} The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dement¹¹
¹Alzheimer's Unit-Memory Clinic, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, - Brescia (Italy), ³Laboratory Of Alzheimer's Neuroimaging And Epidemiology, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, - Brescia, (Italy), ⁴Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa - Genoa (Italy), ⁵Unit Of Behavioral Neurology, Irccs Mondino Foundation, - Pavia (Italy), ⁶Department of Brain and Behavioral Sciences, University of Pavia, - Pavia, (Italy), ⁷Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa, - Genoa (Italy), ⁸IRCCS Ospedale Policlinico San Martino, - Genoa (Italy), ⁹Laboratory Of Neuroimaging Of Aging (lanvie), University Of Geneva, - Geneva (Switzerland), ¹⁰Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, G - Geneva (Switzerland), ¹¹The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia
- P098** A candidate microRNA profile for early diagnosis of sporadic Alzheimer's disease
Maria Tsamou¹, Eva Ntanasi², Faidra Kalligerou², Nicolaos Scarmeas², Susanna Skalicky³, Matthias Hackl³, Erwin L Roggen¹
¹Toxgenolutions - Maastricht (Netherlands), ²1st Department Of Neurology, Aiginition Hospital, National And Kapodistrian University Of Athens Medical School - Athens (Greece), ³Tamira - Wien (Austria)
- P099** Data-driven 18F-Flortaucipir cut-offs for preclinical and early AD
Giulia Quattrini^{1,2}, Clarissa Ferrari³, Michela Pievani¹, Federica Ribaldi⁴, Szymon Tomczyk⁴, Giovanni Battista Frisoni⁴, Valentina Garibotto⁴, Moira Marizzoni¹
¹Laboratory Of Alzheimer's Neuroimaging And Epidemiology (lane), Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ²Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy - Brescia (Italy), ³Unit Of Statistics, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ⁴Memory Clinic And Lanvie-Laboratory Of Neuroimaging Of Aging, University Hospitals And University Of Geneva, Geneva, Switzerland - Geneva (Switzerland)
-  **P100** Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration stratified by sex
Irene Cumplido Mayoral^{1,2,3,4}, Marta Milà-Alomà^{1,2,3,4}, Luigi Lorenzini⁵, Alle Meije Wink⁵, Henk J.m.m. Mutsaerts⁵, Sven Haller⁶, Gael Chetelat⁷, Frederik Barkhof^{5,8}, Margherita Carboni⁹, Gwendlyn Kollmorgen¹⁰, Henrik Zetterberg^{11,12,13,14}, Kaj Blennow^{11,12}, Marc Suárez-Calvet^{1,3,4,15}, Verónica Vilaplana¹⁶, Juan Domingo Gispert^{1,3,17}
¹Barcelona Delta Brain Research Center (bbrc), Pasqual Maragall Foundation - Barcelona (Spain), ²Universitat Pompeu Fabra - Barcelona (Spain), ³IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), ⁴CIBER Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), ⁵Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁶CIRD Centre d'Imagerie Rive Droite - Geneva (Switzerland), ⁷Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cycleron - Caen (France), ⁸Institutes of Neurology and Healthcare Engineering, University College London - London (United Kingdom), ⁹Roche Diagnostics International Ltd - Rotkreuz Zg (Switzerland), ¹⁰Roche Diagnostics GmbH - Penzberg (Germany), ¹¹Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), ¹²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹³Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), ¹⁴UK Dementia Research Institute at UCL - London (United Kingdom), ¹⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹⁶Department of Signal Theory and Communications, Universitat Politècnica de Catalunya - Barcelona (Spain), ¹⁷Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) - Madrid (Spain)
-  **P101** Cerebrospinal fluid placental growth factor in relation to cerebrovascular disease and diabetes in non-demented elderly
Eske Christiane Gertje^{1,2}, Shorena Janelidze¹, Danielle Van Westen^{3,4}, Erik Stomrud^{1,5}, Sebastian Palmqvist^{1,5}, Oskar Hansson^{1,5}, Niklas Mattsson-Carlgen^{1,6,7}
¹Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ²Department of Internal Medicine, Skåne University Hospital - Lund (Sweden), ³Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University - Lund (Sweden), ⁴Imaging and Function, Skåne University Hospital - Lund (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital - Lund (Sweden), ⁷Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden)

-  **P102** **Plasma AD biomarkers can Predict Hippocampal Atrophy**
Hyung-Ji Kim¹, Jae-Hong Lee²
¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)
-  **P103** **Assessment of Plasma p-tau181 in TANGO, a Phase 2 study of Gosuramemab in Patients with early Alzheimer's Disease**
Julie Czerkowicz¹, Jessica Kong¹, Annie Racine¹, Carrie Rubel¹, Jessica Collins¹, Melanie Shulman¹, Danielle Graham¹, John Beaver¹, Samantha Budd Haerberlein¹
¹Biogen - Cambridge (United States)
-  **P104** **Corneal confocal microscopy and MRI brain volumetry: Prognostic biomarkers for progression from mild cognitive impairment to dementia**
Georgios Ponirakis¹, Rayaz Malik¹
¹Weill Cornell Medicine in Qatar - Doha (Qatar)
-  **P105** **Oligomer biomarkers for preclinical and clinical drug development in neurodegenerative disorders**
 Oliver Bannach^{1,2}, Lara Blömeke^{1,2}, Bettina Kass¹, Alice Chen-Plotkin³, Oliver Peters⁴, Dieter Willbold^{1,5}
¹Forschungszentrum Jülich - Jülich (Germany), ²Attyloid GmbH - Düsseldorf (Germany), ³University of Pennsylvania - Philadelphia (United States), ⁴Charité Universitätsmedizin Berlin - Berlin (Germany), ⁵Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany)
-  **P106** **Exploratory study on the proteomic and transcriptomic content of plasma extracellular vesicles in AD patients**
Maria Solaguren-Beascoa¹, Ana Gámez-Valero^{1,2}, Ana M. Ortiz³, Carla Minguet³, Ricardo Gonzalo³, Georgia Escaramís^{1,2}, Montserrat Costa³, Eulàlia Martí^{1,2}
¹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Institut of Neurociencies, Universitat de Barcelona - Barcelona (Spain), ²Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP) - Barcelona (Spain), ³Grifols Bioscience Research Group - Barcelona (Spain)
-  **P107** **Towards the development and validation of a general-purpose regulatory-grade neuroimage analysis tool**
Nick Henscheid¹, Ioannis Pappas², Ryan Cabeen², Jagdeep Podichetty¹, Samuel Hobel², Christopher Weber³, Yashmin Karten¹, Klaus Romero¹, Sudhir Sivakumaran¹, Arthur Toga²
¹Critical Path Institute - Tucson (United States), ²University of Southern California - Los Angeles (United States), ³Alzheimer's Association - Chicago (United States)
- P108** **Bio-Hermes: A Validation Study to Assess a Meaningful Relationship Between Blood and Digital Biomarkers with Aβ PET Scans for Alzheimer's Disease**
 Jennifer Gaudio¹, Sarah Hollingshead¹, John Dwyer¹, Jason Bork¹, Richard Mohs¹, Katy Smith¹, Diana Kerwin², Douglas Beauregard¹
¹Global Alzheimer's Platform Foundation - Washington (United States), ²Kerwin Medical Center - Dallas (United States)
-  **P109** **Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's Disease**
Charisse N. Winston¹, Oliver Lanford², Natalie Levin¹, Rema Raman², Kevin Yarasheski³, Tim West³, Sarah Abdel-Latif², Michael Donohue², Akinori Nakamura⁴, Kenji Toba⁵, Colin L. Masters⁶, James Doecke⁷, Reisa A. Sperling⁸, Paul S. Aisen⁹, Robert A. Rissman¹⁰
¹Department of Neurosciences, University of California San Diego - La Jolla (United States), ²Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Department of Biomarker Research, National Center for Geriatrics and Gerontology - Obu (Japan), ⁵National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, and Tokyo Metropolitan Institute of Gerontology - Obu (Japan), ⁶The Florey Institute, The University of Melbourne - Parkville (Australia), ⁷he Commonwealth Scientific and Industrial Research Organization - Herston Qld (Australia), ⁸Harvard Medical School - Boston (United States), ⁹Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - Los Angeles (United States), ¹⁰Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System - La Jolla (United States)
-  **P110** **Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB**
Mee Young Park¹, Dong Sung Shin¹
¹Neurology Yeungnam University Medical Center - Daegu (Korea, Republic of)
-  **P111** **pTau181 plasma biomarker performance as an inclusion criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer's disease**
Anna Mammel¹, Pankaj Kumar², Lindsay Burns³, Donald Biehl¹, Mary Encarnacion², Anna Cruz², Ging-Yuek Robin Hsiung⁴, Ian Mackenzie⁴, Veronica Hirsch-Reinshagen⁴, Ali Mousavi², Ryan Fortna^{1,5}, James Kupiec³, Hans Frykman^{2,4}
¹Neurocode - Bellingham, Washington (United States), ²BC Neuroimmunology - Vancouver (Canada), ³Cassava Sciences - Austin, Texas (United States), ⁴University of British Columbia - Vancouver (Canada), ⁵Northwest Pathology - Bellingham, Washington (United States)
-  **P112** **Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials**
Hugo Vanderstichele¹, Mahsan Rafizadeh², Erika Cline², Johnson Derrick³, Erica Simmons³, Robert Dean², Jasna Jeretic²
¹Biomarkable - Gent (Belgium), ²Acumen Pharmaceuticals - Charlottesville (United States), ³B2S Life sciences - Indianapolis (United States)
-  **P113** **Detection of CSF alpha-synuclein in patients with prodromal Lewy body disease**
Melanie Plastini¹, Carla Abdelnour¹, Marian Shahid¹, Manuel Medina², Nelson Kha², Hanna Hovren², Jennifer Lamoureux², Victor Henderson¹, Kathleen Poston¹
¹Stanford University - Palo Alto (United States), ²Amprion Clinical Laboratory - San Diego (United States)
-  **P114** **Effect of butyrylcholinesterase genotype on patients with Alzheimer's disease treated with rivastigmine**
Hairin Kim^{1,2}, So Yeon Cho³, Gieun Nam², Kichul Kim^{4,2}, Eosu Kim³, Jun-Young Lee²
¹Emocog Inc. - Seoul (Korea, Republic of), ²Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center - Seoul (Korea, Republic of), ³Department of Psychiatry, Institute of Behavioral Science in Medicine, Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine - Seoul (Korea, Republic of), ⁴Epi Biotech Co., Ltd. - Incheon (Korea, Republic of)

-  **P115** **Impact of Alzheimer's Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial**
Joshua Grill¹, Rema Raman², Garrett Miller², Karin Ernstrom², Michael Donohue², Paul Aisen², Reisa Sperling³, David Henley⁴, H. Robert Brashear⁴, Gary Romano⁴, Gerald Novak⁴
¹University of California Irvine - Irvine (United States), ²Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA - San Diego (United States), ³Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA - Boston (United States), ⁴Janssen Research & Development LLC - Titusville (United States)
-  **P116** **Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers in a Phase 2 Trial in Mild-to-Moderate Alzheimer's Disease (Lauriet)**
Stephen Schauer¹, Julie Lee¹, Veronica Anania¹, Balazs Toth¹, Lee Honigberg¹, Kristin Wildsmith¹, Vidya Ramakrishnan¹, Michael Dolton¹, Sandra Sanabria Bohorquez¹, Edmond Teng¹, Cecilia Monteiro¹
¹Genentech, Inc. - South San Francisco (United States)
-  **P117** **Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood**
Carine Lim¹
¹Sunbird Bio - Singapore (Singapore)
-  **P118** **Recruitment of amyloid positive individuals and early Alzheimer's patients in a primary care setting – results from the BioFINDER Primary Care study**
Sebastian Palmqvist¹, Pontus Tideman¹, Erik Stomrud¹, Ruben Smith¹, Antoine Leuzy¹, Sadek Jafar Jasem¹, Niklas Mattsson-Carlgen¹, Anna Orduña Dolado¹, Shorena Janelidze¹, Oskar Hansson¹
¹Lund University - Malmö (Sweden)
-  **P119** **Deep plasma and CSF proteomics profiling of the AMBAR study**
Chunmiao (mia) Feng¹, Ricardo Gonzalo², Carla Minguet², Pilar Lafuente², Ana Maria Ortiz², Scott Lohr¹, Mercè Boada³, Oscar López⁴, Antonio Paez², Steven Braithwaite¹, Montserrat Costa², Benoit Lehallier¹
¹Alkermes, a Grifols company - San Carlos (United States), ²Grifols - Barcelona (Spain), ³Universitat Internacional de Catalunya - Barcelona (Spain), ⁴University of Pittsburgh - Pittsburgh (United States)
-  **P120** **Association of neighborhood-level socioeconomic disadvantage with CSF biomarkers of Alzheimer's disease and neurodegeneration**
Gilda Ennis¹, Megan Zuelsdorff¹, Ryan Powell¹, Tobey Betthausen¹, William Buckingham¹, Yue Ma¹, Carol Van Hulle¹, Margherita Carboni², Gwendlyn Kollmorgen³, Carey Gleason¹, Sterling Johnson¹, Kaj Blennow⁴, Henrik Zetterberg⁴, Amy Kind¹, Barbara Bendlin¹
¹University of Wisconsin - Madison - Madison (United States), ²Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ³Roche Diagnostics GmbH - Penzberg (Germany), ⁴University of Gothenburg - Gothenburg (Sweden)
-  **P121** **Plasma pTau-217 in preclinical Alzheimer's disease**
Erin Jonaitis¹, Shorena Janelidze², Karly Cody¹, Rebecca Langhough Kosciak¹, Lianlian Du¹, Nathaniel Chin¹, Niklas Mattsson-Carlgen², Kirk Hogan¹, Bradley Christian¹, Tobey Betthausen¹, Oskar Hansson², Sterling Johnson¹
¹University of Wisconsin-Madison - Madison, WI (United States), ²Lund University - Lund (Sweden)
- P122** **Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies**
Stephanie Loomis¹, Ryan Miller¹, Carmen Castrillo-Viguera¹, Kimberly Umans¹, Wenting Cheng¹, John O'gorman¹, Richard Hughes¹, Samantha Budd Haeberlein¹, Christopher Whelan¹
¹Biogen - Cambridge (United States)
- P123** **Low plasma Aβ42/Aβ40 ratio in older adults with enlarged perivascular spaces**
Arunima Kapoor¹, Aimee Gaubert¹, Amy Nguyen¹, Belinda Yew², Jung Yun Jang¹, Shubir Dutt², Yanrong Li¹, John P. Alitin³, Jean K Ho¹, Anna E. Blanken², Isabel J Sible², Anisa Marshall², Alessandra Martini¹, Elizabeth Head¹, Daniel A Nation¹
¹University of California, Irvine - Irvine (United States), ²University of Southern California - Los Angeles (United States), ³University of California, Irvine - Irvine (United States) - Irvine (United States)
-  **P124** **NADALS: An open-label basket trial evaluating the JAK inhibitor baricitinib in Alzheimer's Disease and Amyotrophic Lateral Sclerosis**
Shayda Daneshvari¹, Pia Webb¹, Anne-Marie Wills¹, James Berry¹, Steven Arnold¹, Mark Albers¹
¹MGH - Boston (United States)
-  **P125** **Examining the trajectory of neurodegeneration biomarkers and its association with cognitive profiles and amyloid in late middle-aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)**
Lianlian Du^{1,2,4}, Tobey Betthausen^{1,3,4}, Karly Cody^{1,3,4}, Erin Jonaitis^{1,3,4}, Cory Burghy¹, Bruce Hermann^{1,5}, Bret Larget⁶, Rick Chappell^{3,2}, Sterling Johnson^{1,3,4,7}, Rebecca Kosciak^{1,3,4}
¹Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ²Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison - Madison, WI (United States), ³Wisconsin Alzheimer's Disease Research Center - Madison, WI (United States), ⁴Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁵Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁶Department of Statistics, University of Wisconsin-Madison - Madison, WI (United States), ⁷Madison VA GRECC, William S. Middleton Memorial Hospital - Madison, WI (United States)

THEME: Cognitive and Functional Endpoints

-  **P126** Visit-to-visit blood pressure variability and cognition in the SPRINT MIND trial
Isabel Sible¹, Daniel Nation²
¹Usc - Los Angeles (United States), ²Uc Irvine - Irvine (United States)
-  **P127** Classification and Prediction of Different Cognitive Trajectories in Cognitively Normal Elderly
 Young Ju Kim¹, Si Eun Kim², Alice Hahn³, Soo Hyun Cho⁴, Duk L. Na¹, Jun Pyo Kim¹, Hyemin Jang¹, Hee Jin Kim¹, Juhee Chin¹, Sang Won Seo¹
¹Samsung Medical Center - Seoul (Korea, Republic of), ²Haeundae Paik Hospital - Busan (Korea, Republic of), ³Johns Hopkins Bloomberg School Of Public Health - Baltimore (Korea, Republic of), ⁴Chonnam National University Hospital - Chonnam (Korea, Republic of)
-  **P128** What's in a score: Comparing and aligning scores based on item response theory and classical test theory for the Amsterdam Instrumental Activities of Daily Living Questionnaire
Mark Dubbelman¹, Merel Postema¹, Roos Jutten², John Harrison¹, Craig Ritchie³, Benjamin Schalet⁴, Caroline Terwee⁵, Wiesje Van Der Flier¹, Philip Scheltens¹, Sietske Sikkes¹
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³University Of Edinburgh - Edinburgh (United Kingdom), ⁴Department Of Medical Social Sciences, Feinberg School Of Medicine, Northwestern University - Chicago (United States), ⁵Amsterdam Umc Location Vumc, Epidemiology And Data Science, Amsterdam Umc - Amsterdam (Netherlands)
-  **P129** Effects of Dietary Flax Beverage on Memory and Cognition of Patients with Mild Cognitive Impairment
Aida Adlimoghaddam¹, Nancy Olson², Benedict Albensi³
¹Clinical Research Associate - Winnipeg (Canada), ²Clinical Trial Investigator (Canada), ³Professor (Canada)
-  **P130** A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Investigation of Safety and Efficacy of Nilotinib BE in Early Alzheimer's Disease (NILEAD)
Yasar Torres-Yaghi¹, Marwan Sabbagh², Chris Hoyt³, Kimberly Guedes³, Fernando Pagan¹, Raymond Turner¹, Jaeil Ahn¹, Charbel Moussa¹
¹Georgetown - Washington, DC (United States), ²Barrow - Phoenix, AZ (United States), ³Keiferx - Washington, DC (United States)
-  **P131** Subjective illness representations in an early-stage Alzheimer's disease population: psychometric properties of the RADIX questionnaire
 Alberto Villarejo-Galende¹, Elena García-Arcelay², Gerard Piñol-Ripoll³, Antonio Del Olmo-Rodríguez⁴, Felix Viñuela⁵, Mercè Boada⁶, Emilio Franco-Macias⁷, Almudena Ibañez De La Peña⁸, Mario Riverol⁹, Jorge Maurino²
¹Department Of Neurology, Hospital Universitario 12 De Octubre - Madrid (Spain), ²Medical Department, Roche Farma - Madrid (Spain), ³Unitat Trastorns Cognitius, Hospital Universitari De Santa Maria - Lleida (Spain), ⁴Department Of Neurology, Hospital Universitario Dr. Peset - Valencia (Spain), ⁵Department Of Neurology, Hospital Universitario Virgen Macarena - Sevilla (Spain), ⁶Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁷Department Of Neurology, Hospital Universitario Virgen Del Rocío - Sevilla (Spain), ⁸Centro De Investigación De Parkinson, Policlínica Guipúzcoa - San Sebastián (Spain), ⁹Department Of Neurology, Clínica Universidad De Navarra - Pamplona (Spain)
-  **P132** Impact of Disease Progression on Dependency in Patients with Mild and Moderate Alzheimer Disease
Wenyu Ye¹, Julie Chandler¹, Xiaojuan Mi², Antje Tockhorn-Heidenreich¹, Joseph Johnston¹, Erin Doty¹
¹Eli Lilly And Company - Indianapolis (United States), ²Techdata Services Company - King Of Prussia (United States)
-  **P133** The responsiveness of cognitive and functional outcome measures in preclinical Alzheimer's disease: Implications for trial design
Mark Dubbelman¹, Heleen Hendriksen¹, Lois Ottenhoff¹, Everard Vijverberg¹, Niels Prins², Lior Kroeze¹, Argonde Van Harten¹, Bart Van Berckel¹, John Harrison¹, Wiesje Van Der Flier¹, Sietske Sikkes¹
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands)
-  **P134** The effect of dietary habit on the progression of Alzheimer's disease: A CREDOS (Clinical Research Center for Dementia of South Korea) study
Yangki Minn¹, Seonghye Choi²
¹Kangnam Sacred Heart Hospital, Hallym University - Seoul (Korea, Republic of), ²Inha University Medical Center - Incheon (Korea, Republic of)
-  **P135** Length of administration of ADAS-Cog and CDR assessment impacts data quality
Barbara Echevarria¹
¹WCG Clinical Endpoint Solutions - Hamilton (United States)
-  **P136** Measuring functional impairment in early Alzheimer's disease and related disorders: an overview of the development and validation of the Amsterdam IADL Questionnaire
Sietske Sikkes¹, Mark Dubbelman², Merel Postema², Merike Verrijp³, Freek Gilissen², Wiesje Van Der Flier², Yolande Pijnenburg², Philip Scheltens²
¹Vu University / Amsterdam Umc - Amsterdam (Netherlands), ²Amsterdam Umc, Alzheimer Center - Amsterdam (Netherlands), ³Brain Research Center - Amsterdam (Netherlands)
-  **P137** A Phase 2b, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design
 Aaron Koenig¹, Tiffany Lago¹, Jason Johannesen¹, Sigui Li¹, Emily Freitag¹, Jeffrey Wald¹, Katrina Paumier¹, Michael Quirk¹, James Doherty¹
¹Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)



P138

Bringing meaning to personalised Brain Health: a tool that empowers individuals to define and monitor personally meaningful change

Stina Saunders¹, David Bates², Ankur Bharija^{2,3}, Joyce Gomes-Osman^{2,4}, Saturnino Luz¹, Graciela Muniz-Terrera¹, Álvaro Pascual-Leone^{2,5}, Craig Ritchie¹

¹Centre for Clinical Brain Sciences, University of Edinburgh, UK - Edinburgh (United Kingdom), ²Linus Health Inc., Boston, MA, USA - Boston (United States), ³Department of Medicine, Division of Primary Care and Population Health, Stanford Medicine, Stanford, USA - Stanford (United States), ⁴Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA - Miami (United States), ⁵Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States)

P139

Dementia conversion rate differences between patients with high- and low-risk amnesic mild cognitive impairment in the real-world: A prospective, multicenter, observational study

Hyemin Jang¹, Duk L. Na², Jay Cheol Kwon³, Mee Young Park⁴, Yeonsil Moon⁵, Jung Seok Lee⁶, Kyung-Won Park⁷, Ae Young Lee⁸, Hanna Cho⁹, Jae-Hong Lee¹⁰, Byeong Chae Kim¹¹, Kee Hyung Park¹², Byung-Chul Lee¹³, Hojin Choi¹⁴, Kim Jieun¹⁵, Na-Yeon Jung¹⁶

¹Samsung Alzheimer's Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³Department of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), ⁴Department of Neurology, Yeungnam University College of Medicine - Daegu (Korea, Republic of), ⁵Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine - Seoul (Korea, Republic of), ⁶Department of Neurology, Jeju National University College of Medicine - Jeju (Korea, Republic of), ⁷Department of Neuroscience, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health - Busan (Korea, Republic of), ⁸Department of Neurology, Chungnam National University School of Medicine - Daejeon (Korea, Republic of), ⁹Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ¹⁰Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), ¹¹Department of Neurology, Chonnam National University Medical School & Hospital - Gwangju (Korea, Republic of), ¹²Department of Neurology, College of Medicine, Gachon University Gil Hospital - Incheon (Korea, Republic of), ¹³Department of Neurology, Hallym University College of Medicine - Seoul (Korea, Republic of), ¹⁴Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), ¹⁵Department of Medical, Eisai Korea Inc. - Seoul (Korea, Republic of), ¹⁶Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine - Yangsan (Korea, Republic of)



P140

Predicting tau PET signal in prodromal-to mild Alzheimer's disease from speech biomarkers and machine learning


Mario Mina¹, Johannes Troeger¹, Louisa Schwed¹, Nicklas Linz¹, Sandra Sanabria Bohórquez², Somaye Hashemifar², Tina Boggiano³, Edmond Teng²

¹ki:elements - Saarbruecken (Germany), ²Genentech Inc - San Francisco (United States), ³F. Hoffmann-La Roche Ltd - Basel (Switzerland)

THEME: Cognitive assessment and clinical trials

- P141 **SKT Short Cognitive Performance Test for the detection of early cognitive decline – data from international validation studies**
Mark Stemmler¹
¹University Of Erlangen-Nuremberg - Erlangen (Germany)
-  P142 **ImpACT Cognitive Assessment: What are we measuring**
James Gyurke¹, Phiil Schatz²
¹Riverside Insights - Lutz (United States), ²Saint Joseph's University - Philadelphia (United States)
-  P143 **The effects of the home-based tDCS on behavioral and electrophysiological parameters in MCI and AD comorbid with depression**
Do Hoon Kim¹, Yoo Sun Moon¹
¹Chuncheon Sacred Heart Hospital - Chuncheon (Korea, Republic of)
- P144 **Early-life factors and risk of incident dementia: a longitudinal cohort study**
Ya-Nan Ou¹
¹Qingdao Municipal Hospital - Qingdao (China)
- P145 **Association of socioeconomic status and lifestyle with incident dementia: a prospective cohort study of 276730 UK Biobank participants**
Ya-Nan Ou¹
¹Qingdao Municipal Hospital - Qingdao (China)
- P146 **Association of long-term exposure to ambient air pollution with cognitive decline and Alzheimer's disease-related amyloidosis**
Ya-Hui Ma¹, Lan Tan², Jin-Tai Yu³
¹Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China) - Qingdao (China), ²Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China), ³Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)
-  P147 **Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition – Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment**
Stephen Ruhmel¹, Johannes Tröger², Nicklas Linz², Janna Herrmann², Kai Langel³
¹The Janssen Pharmaceutical Companies Of Johnson & Johnson (United States), ²Ki:elements - Saarbrücken (Germany), ³Ki:elements (United States)
-  P148 **The difference in trajectories according to early amyloid accumulation in normal cognitive elderly**
Young Ju Kim¹, Min Young Chun¹, Hyemin Jang¹, Hee Jin Kim¹, Jeong-Yeon Seo¹, Sang Won Seo¹
¹Samsung Medical Center - Seoul (Korea, Republic of)
- P149 **Risk of seizures and subclinical epileptiform activity in patients with dementia: a systematic review and meta-analysis**
Bing Zhao¹
¹Qingdao Municipal Hospital - Qingdao (China)
-  P150 **Preliminary psychometric and clinical validation of information processing speed in early Alzheimer's Disease using a smartphone-based remote assessment**
Arnaud M. Wolfer¹, Irma T. Kurniawan¹, Kirsten I. Taylor¹, Florian Lipsmeier¹, Thanneer M. Perumal¹
¹Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 - Basel (Switzerland)
- P151 **Differential associations of ApoE-ε2 and ApoE-ε4 genotypes with cerebrospinal fluid biomarkers of Alzheimer's disease in individuals without dementia**
Bing Zhao¹
¹Qingdao Municipal Hospital - Qingdao (China)
-  P152 **Preliminary psychometric and clinical validation of executive function in early Alzheimer's diseases using a smartphone-based assessment**
Irma T. Kurniawan¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Eduardo Aponte¹, Stefan Holiga¹, Thanneer M. Perumal¹, Kirsten I. Taylor¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
-  P153 **Preliminary psychometric and clinical validation of visuospatial working memory deficits in early Alzheimer's Disease measured with a smartphone based digital assessment**
Eduardo A. Aponte¹, Kirsten I. Taylor¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Thanneer M. Perumal¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
-  P154 **The Phase 2 LUMINARY Trial Assessing SAGE-718 in Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease**
Aaron Koening¹, Shishuka Malhotra², Jeffrey Wald¹, Jennifer Petrillo¹, Katrina Paumier¹, Jason Johannesen¹, Sigui Li¹, Michael Quirk¹, Emily Freitag¹, James Doherty¹
¹Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States), ²Neuro-Behavioral Clinical Research, Inc. - North Canton, Ohio (United States)

-  **P155** **Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia**
Kayden Mimmack¹, Emily Sprague^{2,3}, Rebecca Amariglio^{1,2,3}, Patrizia Vannini^{1,2,3}, Gad Marshall^{1,2,3}
¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ³Center for Alzheimer Research and Treatment - Boston (United States)
-  **P156** **Potential Influence of Cognitive Heterogeneity in a Clinical Trial for Mild-to-Moderate Probable Alzheimer's Dementia**
Diane Jacobs¹, Yuqi Qiu², David Salmon¹, Karen Messer¹, Lia Donahue³, Steven Kaplita³, Irfan Qureshi³, Howard Feldman¹
¹University of California San Diego - La Jolla (United States), ²School of Statistics, East China Normal University - Shanghai (China), ³Biohaven Pharmaceuticals, Inc - New Haven (United States)
-  **P157** **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the Alzheimer's Disease Neuroimaging Initiative**
Julie M Chandler¹, Mihaela Georgieva², Urvi Desai², Noam Kirson², Wenyu Ye¹, Andres Gomez-Lievano², Annalise Hilts³, Dody Eid², Angela Zhao², Traci Schilling¹
¹Eli Lilly and Company - Indianapolis (United States), ²Analysis Group - Boston (United States), ³Groupe d'Analyse - Montréal (Canada)
- P158** **Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology**
Jia Hui Hou¹, Jin Tai Yu²
¹Department of Neurology, Qingdao Municipal Hospital, Q - Qing Dao (China), ²Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, - Shang Hai (China)
-  **P159** **Clinical predictors for conversion to Alzheimer's dementia in patients with mild cognitive impairment using Amyloid PET imaging : Interim results**
Kyung Won Park¹, Seon-Jeong Kim¹, Do-Young Kang², Young-Jin Jeong²
¹Department of Neurology, Dong-A University College of Medicine - Busan (Korea, Republic of), ²Department of Nuclear Medicine, Dong-A University College of Medicine - Busan (Korea, Republic of)
-  **P160** **Implementation of the Integrated Cognitive Assessment for Screening and Triaging of Individuals at Risk of Dementia**
Sayed-Mahdi Khaligh-Razavi¹, Chris Kalafatis^{1,2}, Nahida Ahmed³, Tareq Qassem⁴, Farooq Khan⁵
¹Cognetivity Neurosciences - London (United Kingdom), ²Kings College London University - London (United Kingdom), ³Chair of Behavioral Health Council-SEHA - Abu Dhabi (United Arab Emirates), ⁴Maudsley Health, Al-Amal Psychiatric Hospital - Dubai (United Arab Emirates), ⁵Birmingham & Solihull Mental Health NHS Foundation Trust - London (United Kingdom)
-  **P161** **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the National Alzheimer's Coordinating Center**
Julie M Chandler¹, Mihaela Georgieva², Urvi Desai², Noam Kirson², Wenyu Ye¹, Angela Zhao², Dody Eid², Andres Gomez-Lievano², Annalise Hilts³, Traci Schilling¹
¹Eli Lilly and Company - Indianapolis (United States), ²Analysis Group - Boston (United States), ³Groupe d'Analyse - Montréal (Canada)
-  **P162** **Evaluation of cognitive decline in seniors using a single-channel EEG with auditory cognitive assessment**
Lior Molcho¹, Neta Batya Maimon^{2,1}, Talya Zeimer¹, Noa Regev-Plotnik³, Sarit Rabinowicz³, Nathan Intrator^{1,4,5}, Ady Sasson³
¹Neurosteer Inc. - New York, Ny (United States), ²The School of Psychological Sciences, Tel Aviv University - Tel Aviv-Yafo (Israel), ³Dorot Geriatric Medical Center - Netanya (Israel), ⁴Blavatnik School of Computer Science, Tel Aviv University - Tel Aviv (Israel), ⁵Sagol School of Neuroscience, Tel Aviv University - Tel Aviv (Israel)
- P163** **Predictors of memory impairment in mild cognitive impairment with low Mini-Mental State Examination recall scores**
Seon Young Ryu¹, Sang Bong Lee¹, Taek Jun Lee¹, Yu Jin Jung¹
¹The Catholic University of Korea, Daejeon St. Mary's Hospital - Daejeon (Korea, Republic of)
-  **P164** **Increased numbers of modifiable dementia risk factors amplify adverse effects on cognition across the adult lifespan**
Annalise Laplume¹, Larissa Mcketton¹, Brian Levine^{1,2,3}, Angela Troyer^{4,5}, Nicole Anderson^{1,2,6}
¹Rotman Research Institute, Baycrest Health Sciences - Toronto (Canada), ²Department of Psychology, University of Toronto - Toronto (Canada), ³Department of Medicine (Neurology), University of Toronto - Toronto (Canada), ⁴Department Of Psychology, University Of Toronto - Toronto (Canada), ⁵Neuropsychology and Cognitive Health Program, Baycrest Health Sciences - Toronto (Canada), ⁶Department of Psychiatry, University of Toronto - Toronto (Canada)
-  **P165** **Feasibility, Reliability, and Validity of Remote Smartphone Data Collection in Frontotemporal Dementia using the ALLFTD Mobile App**
Adam Staffaroni¹, Jack Taylor¹, Annie Clark¹, Hilary Heuer¹, Amy Wise¹, Masood Manoochehri², Leah Forsberg³, Carly Mester³, Meghana Rao³, Danielle Brushaber³, Julio Rojas¹, Joel Kramer¹, Bradley Boeve³, Howard Rosen¹, Adam Boxer¹
¹UCSF - San Francisco (United States), ²Columbia University - New York (United States), ³Mayo Clinic - Rochester (United States)
-  **P166** **Calculating Generalized Recall Probability Using Digital Cognitive Biomarkers Derived from Wordlist Memory Test Assessment**
Junko Hara^{1,2}, Jason Bock^{1,3}, Kaavya Shah⁴, Dennis Fortier¹, Michael Lee³
¹Embic Corporation - Newport Beach (United States), ²Pickup Family Neuroscience Institute and Hoag Center for Research and Education, Hoag Memorial Hospital - Newport Beach (United States), ³Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ⁴University of California at Berkeley - Berkeley (United States)
-  **P167** **Digital Cognitive Biomarkers for the ADAS-Cog Word Recall Test: Accuracy and Validity of Classifying Cognitive Impairment**
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, William Shankle^{1,2,3}, Michael Lee²
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)


 **P168** **A novel 2-minute high-frequency assessment of episodic memory, shows diurnality, time varying patterns in fatigue and mood which become more tightly coupled with age**
Alexander Anwyl-Irvine¹, Alexander Kaula¹, Nick Taptiklis¹, Cashdollar Nathan¹, Francesca Cormack¹
¹Cambridge Cognition - Cambridge (United Kingdom)

P168bis **Rescreening on RBANS delayed memory index? Forget about it!**
Marwan N Sabbagh¹, Wojciech Michalak², Charlotte Thim Hansen², Lars Lau Raket², Christian Ahmad Wichmann², Alice Clark²
¹Barrow Neurological Institute - Phoenix, Arizona (United States), ²Novo Nordisk A/S - Søborg (Denmark)

THEME: Behavioral disorders and clinical trials

 **P169** **A proof-of-concept study to evaluate efficacy of NanoLithium on the progression of Neuropsychiatric symptoms in patients with mild-to-severe Alzheimer's disease**
Maria Soto¹, Solene Guillot², Pierre-Jean Ousset¹, Davide Angioni¹, Nathalie Sastre Hengan¹, Jean-Claude Maurel², Jacques Touchon³
¹Department Of Geriatrics, Gerontopole, University Hôpital Toulouse, France - Toulouse (France), ²Medesis Pharma - Baillargues (France), ³Montpellier School Of Medicine; University Of Montpellier - Montpellier (France)

P170 **Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology**
Jin-Tai Yu¹, Lan Tan²
¹Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China-Shanghai (china) - Shanghai (China) - Shanghai (China), ²Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)

 **P171** **sTREM2 mediates the associations of minimal depressive symptoms with amyloid pathology in prodromal Alzheimer's disease: The CABLE study**
Wang Zhibo¹
¹Qingdao University - Qingdao (China)

THEME: Health economics and clinical trials

 **P172** **Health economic considerations in the development of a preventive Alzheimer's treatment**
Soeren Matthe¹, Kate Jun¹, Samantha Chu², Mark Hanson¹, Eric Reiman³, Jeffrey Kordower⁴
¹University Of Southern California - Los Angeles (United States), ²Cornell University - Ithaca (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴Arizona State University - Tempe (United States)

 **P173** **Long-Term Care Insurance Service Utilization pattern according to clinical factors of Dementia**
Jun Hong Lee¹
¹National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)


P174 **Cataract, cataract surgery, and risk of incident dementia: a prospective cohort study of 300,823 participants**
Lingzhi Ma¹, Lan Tan¹, Jintai Yu²
¹Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. - Qingdao (China), ²Department Of Neurology And National Center For Neurological Disorders, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Shanghai (China)

 **P175** **Bridging clinical trials and health economic models in Alzheimer's disease**
Linus Jonsson¹, Ron Handels², Colin Green¹
¹Karolinska Institutet - Stockholm (Sweden), ²Maastricht University - Maastricht (Netherlands)

THEME: Epidemiology and clinical trials

 **P176** **Identification of medical conditions as risk factors for mild cognitive impairment – a US claims database study**
Gang Li¹, Toschi Nicola², Batrla Richard³, Galvin James⁴, Henley David⁵, De Santi Susan⁶, Hampel Harald⁶
¹Eisai Inc - Hillsborough (United States), ²Rome University - Rome (Italy), ³Eisai Inc - Basel (Swaziland), ⁴Miami University - Miami (United States), ⁵Janssen - Indianapolis (United States), ⁶Eisai Inc - Nutley (United States)

P177 **Safety of fluorine 18-labeled amyloid tracers: pharmacovigilance validation using a large real-world database**
Kenichiro Sato¹, Yoshiki Niimi², Ryoko Ihara³, Kazushi Suzuki⁴, Atsushi Iwata³, Takeshi Iwatsubo¹
¹University Of Tokyo - Tokyo (Japan), ²University Of Tokyo Hospital - Tokyo (Japan), ³Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), ⁴National Defense Medical College - Saitama (Japan)

 **P178** **Diagnosis and clinical trial recruitment of patients with early onset Alzheimer's disease in clinical practice: Single center experience in Japan**
Masanori Kurihara¹, Ryoko Ihara¹, Kenji Ishibashi², Kenji Ishii², Kazutomi Kanemaru¹, Atsushi Iwata¹
¹Department Of Neurology, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan), ²Research Team For Neuroimaging, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan)

P179 **Socioeconomic status and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 39 prospective studies**
Anyi Wang¹
¹Qingdao University, Qingdao, China - Qingdao (China)





POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 

-  P180 **Globalization of Alzheimer disease clinical trials: recommendations for trial implementation in low- and middle-income countries**
Jorge Llibre-Guerra¹
¹Washington University School Of Medicine In St.louis - St. Louis (United States)
- P181 **Association between multimorbidity status and incident dementia: A prospective cohort study of 245,483 participants**
Heying Hu¹, Jintai Yu², Lan Tan¹
¹Qingdao University - Qingdao (China), ²Fudan University - Shanghai (China)
-  P182 **Generalizability of cognitive results from clinical trial participants to older adult population: addressing external validity**
Vahan Aslanyan¹, Howard N. Hodis^{1,2,3}, Jan St. John^{1,2}, Naoko Kono^{1,2}, Victor Henderson⁴, Wendy J Mack¹
¹Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ²Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ³Department of Medicine, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ⁴Department of Epidemiology and Department of Neurology and Neurological Sciences, School of Medicine, Stanford University - Stanford, Ca (United States)
-  P183 **Cholinesterase inhibitors are associated with large reduction in mortality in patients with Alzheimer's dementia and heart failure**
Maria Eriksdotter¹, Marianne Reimers Wessberg², Johan Fastbom³, Ake Seiger², Hong Xu⁴
¹Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics and Theme Inflammation and Aging, Karolinska University Hospital, Huddinge - Stockholm (Sweden), ²Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics - Stockholm (Sweden), ³Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Aging Research Center - Stockholm (Sweden), ⁴Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics - Stockholm (Sweden) - Stockholm (Sweden)
- P184 **Association between Life's Simple 7 with cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study**
Yong-Li Zhao¹, Jin-Tai Yu²
¹Department of Neurology, Qingdao Municipal Hospital, Qingdao University - Qingdao (China), ²Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontier Center for Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)
- P185 **Hypnotics predict incident dementia and Alzheimer's disease: ADNI cohort and updated meta-analysis of published longitudinal studies**
Jia Hui Hou¹, Wei Xu¹
¹Department of Neurology, Qingdao Municipal Hospital, Qingdao University - Qing Dao (China)
-  P186 **Ultra high risk and high predictability of Alzheimer's disease onset in people with Down syndrome: implications for clinical trials**
Juan Fortea^{1,2,3}, Alberto Lleo^{1,2}, Alexandre Bejanin^{1,2}, Maria Florencia Iulita^{1,2}
¹Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Neurology Department, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ²Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), ³Barcelona Down Medical Center, Fundació Catalana Síndrome de Down - Barcelona (Spain)

THEME: Animal Models and clinical trials

-  P187 **Antidiabetic Drugs in the treatment of Alzheimer's Disease: Perspective from a Drosophila model of Tauopathy and neuroblastoma cells**
Shreyasi Chatterjee¹
¹Nottingham Trent University - Nottingham (United Kingdom)
-  P188 **A novel small molecule inhibitor reduces toxic amyloid oligomers to rescue disease in AD mice**
Vidhu Mathur¹, Kevin Burk¹, Xikun Liu², Sagar Gaikwad³, Rakez Kaye³, Michael T Bowers², Katie Planey¹, Ambuj Singh⁴
¹Acelot Inc. - Santa Barbara (United States), ²Department of Chemistry and Biochemistry, University of California - Lubbock (United States), ³Departments of Neurology & Neuroscience & Cell Biology & Anatomy, University of Texas Medical Branch - Galveston (United States), ⁴Acelot Inc - Santa Barbara (United States)
-  P189 **T-type calcium channel modulator AD101 improves cognitive function in animal models of memory and learning impairment and provides a rationale for the potential clinical use of AD101 in the symptomatic treatment of Alzheimer's disease**
Jan Burmeister¹, Serge Gauthier², Sharon Rogers¹
¹AmyriAD Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)
-  P190 **Effects of T-type calcium channel modulator AD101 on the accumulation of Beta Amyloid, Tau and polyubiquitinated proteins in animal models of Alzheimer's Disease**
Jan Burmeister¹, Serge Gauthier², Sharon Rogers¹
¹AmyriAD Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)

THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions

- P191** Investigating the Efficacy of Tolfenamic acid and its Analogs as Potential Alzheimer's disease Therapeutics
 Jaunetta Hill ¹, Nasser Zawia ^{2,3,4,5}
¹Department Of Biomedical And Pharmaceutical Sciences, University Of Rhode Island - Kingston (United States), ²Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation - Doha (Qatar), ³Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island - Kingston (United States), ⁴Interdisciplinary Neuroscience Program and George and Anne Ryan Institute for Neuroscience, University of Rhode Island - Kingston (United States), ⁵George and Anne Ryan Institute for Neuroscience, University of Rhode Island - Kingston (United States)
- P192** XanaMIA Phase 1b trial with Xanamem® achieves primary endpoints: results and strategic update
Michael Woodward ¹, Paul Rolan ², Miriam Roesner ², Jack Taylor ², Tamara Miller ², Paul Maruff ³
¹Aged Care Research And Memory Clinic, Austin Health - Melbourne (Australia), ²Actinogen Medical - Sydney (Australia), ³Cogstate Ltd - Melbourne (Australia)
- P193** Leveraging untapped national synergies to accelerate representation of Hispanic/Latinos in clinical trials on dementia: the progress of the new Consorcio between the National Association of Hispanic Nurses and the Alzheimer's Association
Elena Portacolone ¹, Adriana Perez ², Carl V. Hill ³, Julio C. Rojas ¹
¹University California San Francisco - San Francisco (United States), ²Penn University - Philadelphia (United States), ³Alzheimer's Association - Chicago (United States)
- P194** Chronic constant light disrupted Circadian Rhythm and induced Alzheimer's Disease-Like Pathology in Rodent and treatment by Fluoxetine
 Ashish Sharma ¹, Mohammad Ashu ², Adesh K Saini ³, Rohit Goyal ²
¹Washington University - Missouri (United States), ²Shoolini University - Solan (India), ³Mm University - Ambala (India)
- P195** Astrocytic Regulatory mechanism on PM2.5-induced neuronal cell death and neuroinflammation
Seol-Heui Han ¹, Ryeong-Eun Kim ², Kyoung Ja Kwon ^{2,3}
¹Department Of Neurology, Konkuk Hospital Medical Center, 120-1 Neungdong-Ro, Gwangjin-Gu - Seoul (Korea, Republic of), ²Department Of Neuroscience, School Of Medicine, Konkuk University - Seoul (Korea, Republic of), ³Department of Neurology, Konkuk Hospital Medical center, 120-1 Neungdong-ro, Gwangjin-Gu - Seoul (Korea, Republic of)
- P196** Impact of Semaglutide in Amyloid Positivity (ISAP): Protocol for a Randomised Double-Blind Placebo-Controlled Trial in Amyloid Positive Individuals
Ivan Koychev ¹, Amanda Adler ¹, Paul Edison ², Brian Tom ³, Joanne Milton ¹, Joe Butchart ⁴, Adam Hampshire ², Charles Marshall ⁵, Elizabeth Coulthard ⁶, Henrik Zetterberg ⁷, Francesca Cormack ⁸, Catherine Mummery ⁹, Rury Holman ¹
¹University of Oxford - Oxford (United Kingdom), ²Imperial College London - London (United Kingdom), ³University of Cambridge - Cambridge (United Kingdom), ⁴Royal Devon University Healthcare NHS Foundation Trust - Exeter (United Kingdom), ⁵Queen Mary University of London - London (United Kingdom), ⁶University of Bristol - Bristol (United Kingdom), ⁷University of Gothenburg - Gothenburg (United Kingdom), ⁸Cambridge Cognition - Cambridge (United Kingdom), ⁹University College London - London (United Kingdom)
- P197** The novel FKBP51-Hsp90 interaction inhibitor attenuates high-fat-induced cognitive impairment
Bengt Winblad ¹, Lisha Wang ¹, Jakub Wojcieszak ¹, Rajnish Kumar ¹, Pavel Pavlov ¹
¹Karolinska Institutet - Stockholm (Sweden)
- P198** Intracellular Aβ accumulation in hippocampal neurons leads to endosomal/lysosomal leakage
Sophia Schedin Weiss ¹, Yang Gao ¹, Lars Tjernberg ¹
¹Karolinska Institutet - Solna (Sweden)
- P199** ALZ-201, a monoclonal antibody therapy for specific neutralisation of toxic amyloid-β in Alzheimer's disease
Anders Sandberg ¹
¹Alzinova AB - Gothenburg (Sweden)
- P200** Reducing toxic amyloid-β oligomers in AD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors
Johnny Habchi ¹, Kerry Jenkins ¹, Samata Pandey ¹, Roxine Staats ¹, Sunehera Sarwat ¹, Benedetta Mannini ¹, Xiaoting Yang ¹, Luke Rajah ¹, Samuel Cohen ¹, Suzanne Brewerton ¹, Alleyn Plowright ¹
¹Wren Therapeutics Limited - Cambridge (United Kingdom)
- P201** The bromodomain and extraterminal domain protein inhibitor apabetalone inhibits the neurotoxic kynurenine pathway in monocytes and brain endothelial cells
 Sylwia Wasiak ¹, Li Fu ¹, Stephanie Stotz ¹, Dean Gilham ¹, Laura Tsujikawa ¹, Chris Sarsons ¹, Jeffrey Kroon ², Erik Stroes ², Norman Wong ¹, Michael Sweeney ³, Jan Johansson ³, Ewelina Kulikowski ¹
¹Resverlogix - Calgary (Canada), ²University of Amsterdam - Amsterdam (Netherlands), ³Resverlogix - San Francisco (United States)
- P202** A novel therapeutic approach to treat Alzheimer's disease: The brain-specific signal peptide peptidase-like 2b (SPPL2b)
Simomne Tamaro ¹, Riccardo Maccioni ², Caterina Trivisan ³, Stefania Zerial ³, Annika Wagener ⁴, Yuniesky Andrade-Talavera ¹, Federico Picciau ², Caterina Grassi ⁵, Gefei Chen ⁶, André Fisahn ¹, Bernd Schröder ⁷, Per Nilsson ¹
¹Department of Neurobiology, Care Sciences and Society (NVS) Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), ²Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), ³Department of life science, University of Trieste - Trieste (Italy), ⁴Interdisciplinary center for Neuroscience, Heidelberg University - Heidelberg (Germany), ⁵Department of Pharmacy and Biotechnology, University of Bologna - Bologna (Italy), ⁶Department of Biosciences and Nutrition, Karolinska Institutet - Huddinge (Sweden), ⁷Institute of Physiological Chemistry, Technische Universität Dresden - Dresden (Germany)

-  **P203** **Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A β amyloidosis**
Richeng Jiang ¹, Una Smalivoc ¹, Hazal Haytural ¹, Betty Tijms ², Hao Li ¹, Ganna Shevchenko ³, Johan Gobom ⁴, Sofie Nyström ⁵, Per Hammarström ⁵, Stina Syvänen ³, Henrik Zetterberg ⁴, Bengt Winblad ¹, Jonas Bergquist ³, Pieter Jelle Visser ², Per Nilsson ¹
¹Karolinska Institutet - Stockholm (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³Uppsala University - Uppsala (Sweden), ⁴Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), ⁵Linköping University - Linköping (Sweden)
-  **P204** **Antibodies generated against an A β -derived oligomer: Efforts toward a novel Alzheimer's disease immunotherapy**
Chelsea Marie Parrocha ¹, Adam Kreutzer ², Jesse Pascual ³, Cherie Stringer ³, Jennifer Nguyen ¹, Ashley Ith ¹, Elizabeth Head ³, James Nowick ^{2,1}
¹Department of Pharmaceutical Sciences, University of California Irvine - Irvine (United States), ²Department of Chemistry, University of California Irvine - Irvine (United States), ³Department of Pathology and Laboratory Medicine, University of California Irvine - Irvine (United States)

THEME: Digital Health/E-Trials

- P205** **Assessment of deep learning algorithm of diagnosing Alzheimer's disease with Korean elderly**
Jong Bin Bae ¹, Ji Won Han ¹, Ki Woong Kim ^{1,2,3,4}, Jun Sung Kim ^{2,5}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of), ⁴Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, South Korea - Seoul (Korea, Republic of), ⁵Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of)
- P206** **A case-control clinical trial on the diagnostic performance for Alzheimer's Disease of a deep learning-based classification system using brain magnetic resonance imaging of Korean elderly**
Jun Sung Kim ^{1,2}, Jong Bin Bae ¹, Subin Lee ³, Ji Won Han ⁴, Ki Woong Kim ^{4,5,2}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department Of Electrical And Computer Engineering, Seoul National University, Seoul, Korea - Seoul (Korea, Republic of), ⁴Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seoul (Korea, Republic of), ⁵Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of)
-  **P207** **The Effect of Home-based Cognitive Training Using Workbook and Tablet PC in Presenile Dementia Patients**
Jay Kwon ¹, Kyeongsoo Lee ², Tae-You Kim ³, Tae-Kyeong Eom ¹
¹Department Of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), ²Department Of Neurology, Samsung Medical Center - Changwon (Korea, Republic of), ³Department Of Neurology, Busan Wili Hospital - Busan (Korea, Republic of)
- P208** **Efficacy of the 'Finger-to-brain' game on cognitive function of older adults with mild cognitive impairment: a randomized controlled crossover trial**
Ji Won Han ^{1,2}, Dong Gyu Moon ¹, Jung Uk Shin ¹, Yeseung Park ³, Min Jeong Kwon ³, Hae In Kim ³, Woori Moon ¹, Dae Jong Oh ^{4,2}, Jong Bin Bae ^{1,2}, Ki Woong Kim ^{5,2,3}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of), ²Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Department Of Brain And Cognitive Science, Seoul National University College Of Natural Sciences - Seoul (Korea, Republic of), ⁴Department Of Psychiatry, Sng-Snu Boramae Medical Center - Seoul (Korea, Republic of), ⁵Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-si (Korea, Republic of)
-  **P209** **Feasibility, acceptability, and adherence of a remote smartphone-based self-assessment of cognition, function, and behavior in early Alzheimer's disease**
Thanneer Malai Perumal ¹, Arnaud Wolfer ¹, Miguel Veloso ², Irma T. Kurniawan ¹, Gollou Keita ³, Niels Hagenbuch ⁴, Beijue Shi ⁵, Foteini Orfanidou ⁶, David Watson ⁷, Mercè Boada Rovira ⁸, Kirsten I. Taylor ²
¹Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ³Cytel Inc., - Geneva (Switzerland), ⁴Global Product Development Data And Statistical Sciences, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ⁵Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁶Global Product Development, Personalized Healthcare, Digital Health, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁷Alzheimer's Research And Treatment Center - Wellington (United States), ⁸Networking Research Center On Neurodegenerative Diseases (ciberned), Instituto De Salud Carlos Iii - Madrid (Spain)
- P210** **Effect of internet-based mindfulness training on cognitive and psychological well-being and EEG brain activity in the elderly: preliminary results**
Samantha Galluzzi ¹, Mariangela Lanfredi ¹, Alberto Chiesa ², Cristina Festari ¹, Serena Meloni ¹, Roberta Rossi ¹, Evita Tomasoni ¹, Davide Moretti ¹, Michela Pievani ¹
¹IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli - Brescia (Italy), ²Istituto Mente e Corpo and Associazione di Psicologia Cognitiva - Scuola di Psicoterapia Cognitiva - Bologna, Rome (Italy)
-  **P211** **Increasing Study Power via Frequent Speech-Based Assessments of Cognition**
Gabriela Stegmann ¹, Shira Hahn ¹, Julie Liss ¹, Visar Berisha ¹, Kimberly Mueller ²
¹Arizona State University and Aural Analytics - Scottsdale, Az (United States), ²iversity of Wisconsin - Madison - Madison, Wi (United States)
-  **P212** **A Multimodal Deep Learning Approach to Prediction of Cognitive Decline and its Potential Application in Clinical Trials for Alzheimer's Disease**
Caihua Wang ¹, Yuanzhong Li ¹, Hiroyuki Yamaguchi ², Hisateru Tachimori ³, Atsushi Sekiguchi ⁴, Yuichi Yamashita ²
¹Imaging Technology Center, FUJIFILM Corporation - Kanagawa (Japan), ²Department of Information Medicine, National Institute of Neuroscience, National Center of Neurology and Psychiatry - Tokyo (Japan), ³Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry - Tokyo (Japan), ⁴Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry - Tokyo (Japan)

-  **P213** **Preliminary Results of a Digital Pilot to Improve AD Trial Retention by Managing Caregiver Stress**
 Rosemary Laird ^{1,2}, Jessica Branning ¹
¹ClinCloud Clinical Trials - Viera (United States), ²Navigating Aging Needs LLC - Orlando (United States)
- P214** **Brain Network Difference between Mild Cognitive Impairment and Alzheimer's Disease Dementia Using EEG**
 Hong Yuseong ¹, Baik Kyoungwon ², Park Ukeob ¹, Ye Byoung Seok ², Kang Seung Wan ¹
¹MediSync Inc. - Seoul (Korea, Republic of), ²Yonsei University College of Medicine - Seoul (Korea, Republic of)
-  **P215** **Using Ecological Momentary Assessment to Measure Real-World Effects of a Combined Computerized Cognitive and Functional Skills training Program in Mild Cognitive Impairment**
 Philip Harvey ¹, Peter Kallestrup ², Sara Czaja ³
¹University of Miami Miller School of Medicine - Miami (United States), ²i-Function - Miami (United States), ³Weill Cornell Medical Center - New York (United States)
-  **P216** **The effects of home-based cognitive intervention with chat-bot on brain function in patients with amnesic mild cognitive impairment**
 Geon Ha Kim ¹, Bori Kim ¹, Jee Hyang Jeong ¹
¹EwhaW.University - Seoul (Korea, Republic of)
- P217** **Remote computer-based cognitive training: short- and long-term benefits on cognition and daily living in patients with Alzheimer's disease**
 Samar Dimachki ¹, Franck Tarpin-Bernard ², Stéphanie De Chalvron ², Bernard Croisile ³, Hanna Chainay ¹
¹Laboratoire d'Étude des Mécanismes Cognitifs, Université Lyon 2 - Lyon (France), ²Scientific Brain Training SA - Lyon (France), ³Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital Neurologique - Lyon (France)
-  **P218** **Taking care of family dementia caregivers: A qualitative examination of patient perspectives and perceived health outcomes after receiving usual care and after a digitally supported care management program**
 Olga Klein ¹, Antonia Karras ², Wolfgang Hoffmann ^{3,4}, Stefan Teipel ^{1,2}, Ingo Kilimann ^{1,2}
¹Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Rostock (Germany) - Rostock (Germany), ²Clinic for Psychosomatics and Psychotherapy, University Medical Center Rostock - Rostock (Germany), ³Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Greifswald (Germany), ⁴Institute for Community Medicine, Section Epidemiology and Community Health, University Medicine Greifswald - Greifswald (Germany)
-  **P219** **Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer's and related dementias**
 Monroe Butler ¹, Anton Porsteinsson ², Sean Kenny ¹, Hansen Lenyoun ³, Matt Hobbs ¹, Roland Brown ¹, Matt Bianchi ³, James Williams ¹, Audrey Gabelle ¹, Shibeshih Belachew ¹, Intuition Study Scientific Committee Intuition Study Scientific Committee ¹
¹Biogen - Cambridge (United States), ²University of Rochester Medical Center - Rochester (United States), ³Apple - Cupertino (United States)
-  **P220** **Cognitive health in underrepresented populations: early learnings from the Intuition brain health study**
 Rhoda Au ¹, Monroe Butler ², Hanson Lenyoun ³, Sean Kenny ², Roland Brown ², Paramita Saha-Chaudhuri ², Matt Bianchi ³, James Williams ², Audrey Gabelle ², Shibeshih Belachew ², Intuition Study Scientific Committee Intuition Study Scientific Committee ²
¹Boston University School of Medicine - Boston (United States), ²Biogen - Cambridge (United States), ³Apple - Cupertino (United States)
-  **P221** **Analyzing Facial Expressions and Poses Captured During Video Chats for Early Identification of MCI - Proof of Concept Study: I-CONNECT Project**
 Muath Alsuhaibani ¹, Ali Pourramezan Fard ¹, Hiroko Dodge ^{2,3}, Mohammad Mahoor ¹
¹School of Electrical and Computer Engineering, University of Denver - Denver (United States), ²Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University - Portland (United States), ³Oregon Center for Aging and Technology (ORCATECH), Oregon Health & Science University - Portland (United States)
-  **P222** **Using AI and Natural Language Processing Algorithms to Screen Older Adults with Mild Cognitive or Early Alzheimer's Disease**
 Stephanie Melgar-Donis ^{1,2}, Jarid Siewierski ³, Rohola Zandie ^{1,3}, Daniel Pittman ¹, Lombe Chileshe ¹, Hojjat Abdollahi ³, Maryam Habibi ³, Brock Soicher ³, Eshrat Emamian ³, Mohammad Mahoor ^{3,4}
¹University of Denver - Denver (United States), ²DreamFace Technologies, LLC, ³DreamFace Technologies, LLC - Centennial, Co (United States), ⁴Univesrity of Denver - Denver (United States)



CTAD 2022 VENUE

CTAD 2022 will be held at the **Hilton Union Square**

333 O'Farrell Street

San Francisco, CA 94102, USA

The hotel is steps from the Curran and ACT theaters and just two blocks from Union Square and Westfield shopping center. The Powell Street cable car turnaround, San Francisco Museum of Modern Art, and Moscone Convention Center are within a mile. Enjoy panoramic views from our skybar, the city's highest.

CTAD has negotiated special rates for its attendees at 296US\$ inclusive of breakfast and exclusive of taxes.

Book at www.ctad-alzheimer.com



Clinical Trials on Alzheimer's Disease

Mark your agenda!

LATE CALL FOR ABSTRACTS
September 15-30

Graphic Design: Melanie Vaisette - @Tiemey

Follow us on social media!



[@CTADConference](#)
[#CTAD22](#)



[CTAD Conference](#)



[CTAD Alzheimer](#)

Email: ctad@ant-congres.com
www.ctad-alzheimer.com